1	Genetic influences on circulating retinol and its relationship to human
2	health
3	William R. Reay <sup>1,2,3*</sup> , Dylan J. Kiltschewskij <sup>1,2</sup> , Maria A. Di Biase <sup>3,4,5</sup> , Zachary F. Gerring <sup>6</sup> ,
4	Kousik Kundu <sup>7,8</sup> , Praveen Surendran <sup>9,10,11</sup> , Laura A. Greco <sup>1,2</sup> , Erin D. Clarke <sup>12,13</sup> , Clare E.
5	Collins <sup>12,13</sup> , Alison M. Mondul <sup>14</sup> , Demetrius Albanes <sup>15</sup> , Murray J. Cairns <sup>1,2*</sup>
6	
7	1. School of Biomedical Sciences and Pharmacy, The University of Newcastle,
8	Callaghan, NSW, Australia.
9	2. Precision Medicine Research Program, Hunter Medical Research Institute, New
10	Lambton, NSW, Australia.
11	3. Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of
12	Melbourne, Melbourne, VIC, Australia.
13	4. Department of Anatomy and Physiology, The University of Melbourne, Melbourne,
14	VIC, Australia.
15	5. Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School,
16	Boston, MA, USA.
17	6. QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
18	7. Human Genetics, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton,
19	Cambridge, UK.
20	8. Department of Haematology, University of Cambridge, Cambridge Biomedical
21	Campus, Cambridge, UK.
22	9. British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public
23	Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
24	10. British Heart Foundation Centre of Research Excellence, School of Clinical
25	Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
26	11. Health Data Research UK, Wellcome Genome Campus and University of
27	Cambridge, Hinxton, UK.
28	12. School of Health Sciences, The University of Newcastle, Callaghan, NSW, Australia.
29	13. Food and Nutrition Research Program, Hunter Medical Research Institute, New
30	Lambton, NSW, Australia.
31	14. Department of Epidemiology, University of Michigan School of Public Health, Ann
32	Arbor, Michigan, USA.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 33 15. Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH,

- 34 Department of Health and Human Services, Bethesda, MD, USA.
- 35
- 36 To whom correspondence should be addressed:
- 37 Dr William Reay, Medical Sciences Building, University Drive, The University of
- 38 Newcastle, Callaghan, NSW, Australia, 2308. Email: <u>william.reay@newcastle.edu.au</u>
- 39 or Prof Murray Cairns, Medical Sciences Building, University Drive, The University of

40 Newcastle, Callaghan, NSW, Australia, 2308, Email: <u>murray.cairns@newcastle.edu.au</u>

41

#### 42 ABSTRACT

Retinol is a fat-soluble vitamin that plays an essential role in many biological processes 43 throughout the human lifespan. Previous work has characterised genetic influences on 44 circulating retinol; however, small sample sizes have limited our ability to fully appreciate the 45 genetic architecture of this trait. In this study, we performed the largest genome-wide 46 47 association study (GWAS) of retinol to date in up to 22,274 participants. We identified eight common variant loci associated with retinol, as well as a rare-variant signal. An integrative 48 gene prioritisation pipeline supported novel retinol-associated genes outside of the main retinol 49 transport complex (RBP4:TTR) related to lipid biology, energy homeostasis, and endocrine 50 signalling. Genetic proxies of circulating retinol were then used to estimate causal relationships 51 52 with almost 20,000 clinical phenotypes via a phenome-wide Mendelian randomisation study (MR-pheWAS). The MR-pheWAS suggested that retinol may exert causal effects on 53 54 inflammation, adiposity, ocular measures, the microbiome, and MRI-derived brain phenotypes, amongst several others. Conversely, circulating retinol may be causally influenced by factors 55 56 including lipids and renal function. Finally, we demonstrated how a retinol polygenic score could identify individuals who are more likely to fall outside of the normative range of 57 circulating retinol for a given age. In summary, this study provides a comprehensive evaluation 58 59 of the genetics of circulating retinol, as well as revealing traits which should be prioritised for 60 further clinical investigation with respect to retinol related therapies or nutritional intervention.

- 61
- 62
- 63
- 64
- 65
- 66

# 67 INTRODUCTION

Vitamin A is an essential micronutrient that is involved in a range of important biological 68 69 processes, including, vision, immune function, cell division, and neurodevelopment<sup>1,2</sup>. Vitamin A does not refer to a single compound, but rather to a group of compounds that encompasses 70 71 retinol (all-trans retinol), retinoids (metabolites of retinol, such as retinaldehyde and retinoic 72 acid), and provitamin carotenoids (beta-carotene, alpha-carotene, and beta-cryptoxanthin). 73 Retinol is the form of vitamin A dietarily consumed from animal products, along with retinyl 74 ester<sup>3</sup>, while plant-based materials contain precursors termed carotenoids that can be converted to retinaldehyde<sup>4</sup>. Retinoic acid, an oxidised form of retinaldehyde, is a particularly potent 75 76 signalling molecule that regulates the expression of thousands of genes after binding to nuclear receptors including the retinoic-acid receptor and retinoid-X receptor subgroups<sup>5,6</sup>. 77

78

The majority of dietary retinol is delivered to the liver, which is the primary organ responsible for its storage and metabolism. Retinol binding protein 4 (RBP4) is the major systemic transporter of retinol after hepatic secretion, facilitating delivery of retinol throughout the body<sup>3,7,8</sup>. RBP4 in turn complexes with the tetramer protein transthyretin (TTR), which stabilises circulating RBP4 and reduces renal filtration<sup>9</sup>. Notably, retinol can also be delivered directly to target tissues through other mechanisms, such as its postprandial packaging into lipid chylomicrons, as reviewed elsewhere<sup>3</sup>.

86

The role of retinoid-related interventions in human disease for individuals who are not retinol 87 88 deficient has been of long-standing interest. Synthetic retinoids that are structurally similar to retinol/retinoic acid are approved for dermatological indications (e.g., adapalene) and some 89 cancers (e.g., bexarotene)<sup>10,11</sup>, with continued interest in repurposing these compounds across 90 a range of other indications, including neuropsychiatry<sup>2,12</sup>. Currently, retinol supplementation 91 is not specifically indicated unless an individual is deficient, which is rare in high-income 92 countries, though much more common in low-income countries. Numerous observational or 93 randomised controlled studies have explored the effects of supplementation, a high vitamin A 94 diet, and/or measured circulating retinol in a variety of disease contexts. However, the data 95 from these efforts have often either been null or conflicting between studies<sup>12–16</sup>. Despite this, 96 recent observational evidence suggests a relationship between a greater serum retinol 97 abundance and lower mortality in a large, prospective 30-year follow up study<sup>17</sup>. 98

99

100 Genetics provides a powerful tool to better characterise factors that influence the abundance of circulating retinol in serum. Moreover, estimated genetic effects on retinol can be utilised to 101 102 understand potential causal relationships with human health and disease, which may be informative for supplementation, dietary intervention, or drug repurposing<sup>18,19</sup>. Family studies 103 have suggested that circulating retinol is significantly heritable<sup>20</sup>, albeit estimated in small 104 sample sizes. Similarly, dedicated genome-wide association studies (GWAS) of circulating 105 106 retinol have also been limited to very modest sample sizes<sup>21,22</sup>. In 2011, Mondul et al. published findings of two genome-wide significant loci associated with retinol (N = 5006). These loci 107 108 were plausibly mapped to the genes *RBP4* and *TTR*, respectively, which form the primary retinol transport complex<sup>22</sup>. There has been comparatively little progress in further 109 characterising the genetic architecture of retinol since that time relative to other micronutrients 110 like vitamin D, for which large sample size GWAS (N > 400,000) have been released<sup>23,24</sup>. The 111 recent adoption of untargeted high-throughput metabolomics platforms with coverage for 112 retinol in some existing genotyped cohorts presents a new opportunity to boost statistical 113 114 power. As a result, in the current study, we aim to perform the largest GWAS of circulating 115 retinol to-date to identify novel loci and leverage these data to study how retinol relates to 116 health and disease.

117

#### 118 **RESULTS**

119

# 120 The common and rare variant genetic architecture of circulating retinol

121 We integrated common and rare variant data from up to 22,274 individuals of European ancestry in our discovery meta-analyses to estimate genetic effects on circulating retinol 122 123 (Figure 1A-B, Online Methods). Firstly, variants from the INTERVAL and METSIM studies 124 were meta-analysed ( $N_{Meta} = 17,268$  – termed *METSIM+INTERVAL*, Figure 1, Online 125 Methods). After harmonisation, there were 8,173,975 common and 5,091,050 rare [minor allele frequency (MAF) < 1%] overlapping variants between INTERVAL and METSIM, 126 respectively. As retinol effect sizes were estimated in the same units in both studies (plasma 127 128 SD units, quantified by the same instrument), we conducted both a fixed-effects inversevariance weighted (IVW) meta-analysis and a sample-size weighted meta-analysis of Z scores 129 (Stouffer's method). Secondly, we conducted an additional meta-analysis ( $N_{Meta} = 22,274$ ) 130 131 which also included data from two other studies (ATBC and PLCO), termed the METSIM+INTERVAL+ATBC+PLCO meta-analysis. However, there were markedly fewer 132 variants available in this meta-analysis after imputing the ATBC and PLCO summary statistics 133

134 and harmonising with METSIM+INTERVAL (N<sub>Var</sub> = 3,896,351, Online Methods). As a result,

135 we focused on the METSIM+INTERVAL meta-analysis as the primary discovery dataset.

136

Considering common variants from the HapMap3 panel (MAF > 0.05, outside of the major 137 138 histocompatibility complex (MHC) region), we observed a relatively subtle inflation of retinol signals across the genome as indexed by the mean  $\chi^2$  statistic, with mean  $\chi^2$  values around 139 1.03-1.04, regardless of the meta-analysis considered (Supplementary Table 1). Common 140 variant SNP heritability ( $h^2_{SNP}$ ) estimated using the linkage disequilibrium (LD) score 141 142 regression (LDSR) approach and the 1000 genomes European reference panel was between 143 6%-7% and nominally statistically significant, although with somewhat large standard errors (2.6%-3.2%) (Figure 1C, Supplementary Table 2). SNP heritability estimates of circulating 144 retinol increased to between 10%-13%, but were still noisy, using two alternate models to 145 estimate  $h^2_{\text{SNP}}$  and the UK Biobank (UKBB) as the LD reference (Figure 1C, Online Methods, 146 Supplementary Table 2). Partitioned  $h^2_{\text{SNP}}$  across tissues and cell-types demonstrated nominal 147 enrichment in biologically logical contexts such as liver, adipose, pancreas, and blood 148 (Supplementary Figure 1). The somewhat large  $h^2_{\text{SNP}}$  standard errors are likely a product of 149 sample size; however, we then conducted further analysis to explore the extent of the polygenic 150 151 signal associated with retinol across the genome using an Empirical Bayes' method (Online 152 Methods). This method was utilised to model the number of non-null effects on retinol genomewide stratified by bins of LD scores that index the extent of LD a variant exhibits with other 153 variants (Figure 1D). Across all LD score bins, we estimated that the mean fraction of common 154 variants across the genome with non-null effects on retinol was between 1.4% to 2.4%, 155 depending on the modelling parameters used. In line with expectation, the proportion of non-156 157 null retinol effects was very high (> 50%) when considering the variants that display the most extensive LD (highest LD score bins). The application of these analyses to two GWAS of 158 159 another vitamin (25-hydroxyvitamin  $D_3$ ) with either comparable or much larger sample sizes<sup>23,25</sup>, suggested that the less-polygenic architecture of retinol observed in this study may 160 161 become more diffuse across the genome with greater sample sizes, in line with many other 162 quantitative traits (Supplementary Figure 2). However, we caution that further investigation will be required as these data become available to confirm this. 163

164

Next, we processed the common variant results of both meta-analyses to identify genome-wide 165 significant loci associated with circulating retinol ( $P_{\rm GWAS} < 5 \times 10^{-8}$ ). In the primary discovery 166 meta-analysis (METSIM+INTERVAL, Stouffer's method), we uncovered eight genome-wide 167

significant loci, six of which were not reported in the previous Mondul et al. retinol GWAS (Table 1). The absolute effect sizes of these lead SNPs were between 0.066 and 0.172 SD in circulating retinol per effect allele, as derived from the IVW meta-analysis. We observed minimal heterogeneity between the two cohorts for these lead SNPs, although heterogeneity was slightly more marked for rs6601299. Replication was then attempted in the TwinsUK cohort (N up to 1621, Online methods). Considering the mean association across all timepoints retinol was measured, as well as the twin pairs separately, 7 out of the 8 lead SNPs in the loci had effect sizes in the same direction, which was greater than expected by chance alone (Binomial P = 0.035, Supplementary Table 3).

We also investigated the effect of retinol associated lead SNPs on factors associated with dietary intake of retinoids. Using a GWAS of retinol intake derived from a self-reported 24hour dietary recall in the UK Biobank (UKBB, N = 62,991)<sup>26</sup>, we found no evidence to suggest that any of the effect of these genetic signals on circulating retinol is mediated through influencing dietary intake behaviours (Supplementary Table 4, Supplementary Figure 3).

- -

# 201 Table 1. Genome-wide significant common loci associated with retinol

# 202 (METSIM+INTERVAL)

Lead SNP	Locus	EA/	EAF	EAF	Beta	Z-score	<b>P</b> <sub>GWAS</sub>	P <sub>Het</sub>
(Stouffer)		NEA	(NFE)	(FIN)	(IVW)	(Stouffer)		
rs1260326	2:27598097-	T/C	0.409	0.358	0.071	6.242	4.32e <sup>-10</sup>	0.023
	27752871							
rs34898035	2:122078406-	A/G	0.042	0.027	-0.172	-5.677	1.37e <sup>-8</sup>	0.190
	122084285							
rs11762406	7:114014488-	A/C	0.092	0.085	-0.107	-5.526	3.28e <sup>-8</sup>	0.104
	114286611							
rs6601299	8:9167797-	T/C	0.17	0.10	-0.105	-6.197	5.76e <sup>-10</sup>	0.004
	9224907							
rs10882283	10:95295876-	A/C	0.622	0.664	0.109	9.789	1.26e <sup>-22</sup>	0.192
	95360964							
rs12149203	16:79696939-	C/G	0.708	0.726	0.069	5.668	1.45e <sup>-8</sup>	0.841
	79756197							
rs1667226	18:29134171-	A/T	0.481	0.507	-0.092	-8.405	4.27e <sup>-17</sup>	0.06
	29190174							
rs6029188	20:39142516-	A/G	0.637	0.662	-0.066	-5.908	3.47e <sup>-9</sup>	0.147
	39234223							
1					1			

Lead SNP based on statistical significance from sample size weighted (Stouffer) meta-analysis. Loci boundaries as defined by FUMA (hg19 coordinates). EA = effect allele, that is, allele to which the effect size relates, NEA = non-effect allele. The effect allele frequency (EAF) is given from gnomAD v2.1.1 for non-Finnish Europeans (NFE) and Finnish Europeans (FIN). The effect size in standard deviation units (beta) is denoted for each lead SNP from the IVW meta-analysis, as well as the Z-score from the Stouffer meta-analysis. The  $P_{GWAS}$  (statistical significance of association) and  $P_{Het}$  (Heterogeneity between input effect sizes P value derived from Cochran's Q) are also from the Stouffer meta-analysis. Bolded loci are known retinol signals.

211 212

209

210

- \_\_\_\_
- 213
- 214
- 215
- 216

medRxiv preprint doi: https://doi.org/10.1101/2023.08.07.23293796; this version posted August 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity.



Figure 1. Common variant influences on circulating serum retinol. (a) Manhattan plot of the
meta-analysis of common variants shared between the INTERVAL and METSIM cohorts
(Stouffer's sample size weighted meta-analysis). Variant-wise -log<sub>10</sub> P-values for association
are plotted, with the dotted red line denoting genome-wide significance. The closest genic
transcription start site is labelled for each lead SNP. (b) Manhattan plot, as above, for the
larger sample size meta-analysis that includes the ATBC and PLCO cohorts, but with fewer

variants available for meta-analysis (c) Estimates of SNP heritability of retinol  $(h^2)$ , with the 223 error bars denoting the standard errors of the estimates. The first two panels denote estimates 224 225 using the BLD-LDAK model and the LDAK-thin model, respectively, both using LD tagging files from the Great British ancestry participants in the UK Biobank. The last panel estimates 226 heritability using the LDSR model with LD from the 1000 genomes European participants. 227 *Estimates were for the METSIM+INTERVAL meta-analyses (Stouffer's and IVW), as well as* 228 229 the larger meta-analysis including ATBC/PLCO. (d) Empirical Bayes' estimation of non-null effects on retinol genome-wide, stratified by bins of ascendingly sorted LD score by magnitude. 230 The LD score bins were different for each panel – 1000 bins, 1000 genomes European LD 231 scores (top left); 5000 bins, 1000 genomes European LD scores (top right); 1000 bins, UKBB 232 233 white British LD scores (bottom left); 5000 bins, white British LD scores (bottom right). Each point represents the proportion of non-null effect sizes for that bin, with the trendline estimated 234 using a generalised additive model for the relationship between the LD score bin and the 235 236 proportion of non-null effects.

237

In the larger sample-size meta-analysis with fewer variants available across all input datasets 238 239 (*METSIM+INTERVAL+ATBC+PLCO*), six of the eight genome-wide significant loci from the 240 smaller meta-analysis were available to test for association. Five of the six loci available became more statistically significant in this larger meta-analysis, whilst the chromosome 8 241 242 locus obtained a very similar level of statistical significance in both meta-analyses (Table 2). It should be noted that there was relatively large heterogeneity for the lead SNP at the TTR 243 244 locus on chromosome 18 locus between cohorts. This was due to a more significant association 245 in the ATBC+PLCO GWAS, although this region was still very strongly associated in 246 METSIM and INTERVAL in the same direction.

- 247
- 248
- 249
- 250
- 251
- 252
- 253
- 254
- 234
- 255

#### Table 2. Genome-wide significant common loci associated with retinol in the larger 256

#### meta-analysis (METSIM+INTERVAL+ATBC+PLCO) 257

Lead SNP	Locus	EA/	Z-score	Z-score	P <sub>GWAS</sub>	P <sub>Het</sub>
(Stouller)		NLA	(METSIM+ INTERVAL)	(METSIM+ INTERVAL+		
			,	PLCO+		
				ATBC)		
rs1260326	2:27598097-	T/C	6.242	6.714	1.90e <sup>-11</sup>	0.06
	27752871					
rs6601299	8:9167797-	T/C	-6.197	-6.137	8.41e <sup>-10</sup>	0.004
	9224907					
rs11187547	10:95279771-	A/G	8.769	10.691	1.12e <sup>-26</sup>	0.11
	95360964					
rs11865979	16:79696939-	T/C	5.575	6.103	1.04e <sup>-9</sup>	0.887
	79756197					
rs4799581	18:29068068-	T/C	-7.998	-11.065	1.85e <sup>-28</sup>	9.72e <sup>-6</sup>
	29230411					
rs6029188	20:39152458-	A/G	-5.908	-6.407	1.48e <sup>-10</sup>	0.299
	39234223					

258

Lead SNP based on statistical significance from sample size weighted (Stouffer) meta-analysis for 259 SNPs available in this extended analysis. Loci boundaries as defined by FUMA (hg19 coordinates). 260 EA = effect allele, that is, allele to which the effect size relates, NEA = non-effect allele. The Z score is given for the full extended meta-analysis as well as the smaller METSIM+INTERVAL 261 262 analysis in terms of sample size. The  $P_{GWAS}$  (statistical significance of association) and  $P_{Het}$ 263 (Heterogeneity between input effect sizes P value derived from Cochran's Q) are also from the 264 Stouffer meta-analysis from the extended meta-analysis. Bolded loci are known retinol signals.

265

We also estimated rare variant (frequency < 1%) effects on circulating retinol using variants 266 267 available in the METSIM+INTERVAL meta-analysis. Despite relatively low power to detect 268 rare variant association, we identified a genome-wide significant rare variant signal on 269 chromosome five (chr5:86765041:T:C, dbSNP ID: rs138675130) associated with reduced circulating plasma retinol per C allele (-0.441 SD, SE = 0.0709,  $P = 6.37 \times 10^{-9}$ ) with no 270 271 significant heterogeneity between the contributing studies. The frequency of this C allele in Europeans (gnomAD v.3.1.2) ranges from 0.5% in non-Finnish Europeans to 0.8% in Finns, 272

273 and whilst it is marginally rarer in Africans and South Asians, it is entirely absent in the East 274 Asian and Middle Eastern populations in that database. The variant is intergenic and in FinnGen release 8, the C allele was associated at phenome-wide significance ( $P < 1 \times 10^{-5}$ ) 275 with increased odds of benign neoplasm of the eye and adnexa, as well as whooping cough. 276 277 The closest canonical transcription start site to this variant is that of COX7C, which encodes a 278 subunit of a terminal component of the mitochondrial respiratory chain. We also uncovered several suggestively significant rare variant signals ( $P < 1 \times 10^{-5}$ ), including three non-279 synonymous variants in the genes FREM2, NAXD, and CHD1 (Supplementary Table 5). Of 280 281 these, the rare NAXD non-synonymous allele suggestively associated with lower retinol 282 (rs3742192) had some *in silico* evidence to suggest deleteriousness (Supplementary Table 5), although it is classed as benign in ClinVar. Finally, to boost power, we also statistically 283 aggregated rare variants to genes (Online Methods). There were no significant retinol genes 284 after Bonferroni correction of these gene level association results ( $P < 3.02 \times 10^{-7}$ ); however, 285 there were two novel suggestively associated genes ( $P < 3.02 \times 10^{-5}$ ), GALM and ZDHHC18 286 287 (Supplementary Table 6).

288

#### 289 Prioritisation of retinol-associated genes reveals novel mechanisms influencing

#### 290 circulating retinol

291 In common variant loci, prioritising causal genes can be difficult due to confounding factors 292 like linkage disequilibrium. For circulating retinol, we employed a multi-faceted approach to 293 prioritise genes that are confidently associated. Firstly, we sought to interrogate the eight 294 genome-wide significant loci uncovered in the main discovery meta-analysis 295 (METSIM+INTERVAL) to uncover plausible causal genes. This was achieved by adapting an integrative pipeline developed in previous work that considers annotation, probabilistic 296 297 finemapping, integrative scoring, and *in silico* prediction (Online Methods, Supplementary Table 7). We describe these results further for each locus in the supplementary text but 298 299 summarise the prioritisation evidence forthwith. There was quite consistent evidence in four 300 loci for a likely causal gene (GCKR, FOXP2, RBP4, and TTR). RBP4 (chromosome 10 locus) and TTR (chromosome 18 locus) were previously associated with retinol in the only other 301 dedicated GWAS of this trait and form the complex that transports retinol in serum<sup>22</sup>, thereby, 302 having a direct biological link to retinol abundance. GCKR, a gene encoding a protein that 303 304 binds to and regulates the key metabolic enzyme glucokinase, was confidently the causal gene 305 for the locus on chromsome 2 with the rs1260326 lead SNP. This gene is known to have a large

and varied metabolic association profile due to the role of glucokinase in glycaemic and lipid related processes, amongst others<sup>27–29</sup>. Interestingly, the lead SNP, and most likely causal variant derived from probabilistic finemapping, was a common missense allele (rs1260326), whereby the retinol increasing *T* allele corresponds to a substitution of leucine for proline in the GCKR protein. Previous experimental work suggests that this variant impacts GCKR affinity for glucokinase<sup>27,30</sup>.

312

The transcription factor gene FOXP2 was also strongly supported by multiple lines of evidence 313 314 as a causal gene for the locus on chromosome seven. The role of this gene in the brain and in relation to neurological phenotypes like language has been extensively studied<sup>31</sup>, but less so in 315 316 the periphery despite relatively high expression across many different systemic tissues. Therefore, we analysed RNA-sequencing data of FOXP2 overexpression in a cell-line not 317 derived from the central nervous system (human osteosarcoma epithelial cell line) and revealed 318 the transcriptional correlates of FOXP2 overexpression were enriched for a broad range of 319 320 pathways related to factors including extracellular matrix biology, glycosylation, and 321 interleukin signalling, amongst many others (Supplementary Tables 8-11, Online Methods).

322

323 The remaining four loci exhibited less clear evidence of which gene to prioritise, although all point to potentially interesting functional mechanisms. On chromosome eight, there is some 324 325 evidence to support *PPP1R3B* as a gene that influences retinol, which encodes a catalytic 326 subunit of the phosphatase PP1 that is implicated in relevant metabolic processes like glycogen 327 synthesis<sup>32</sup>. However, other lines of evidence point to a role of long-noncoding RNA in this locus. The loci on chromosomes 16 and 20 are noteworthy as the closest transcription start sites 328 329 to the respective lead SNPs are two transcription factors (TF) from the *Maf* family (*MAF* and MAFB). Interestingly, MAFB has been shown to regulate both TTR and RBP4 expression in 330 various tissue contexts from human or murine studies<sup>33,34</sup>. As only some lines of evidence 331 support these two TF, further functional characterisation of these two loci is warranted. 332 Interestingly, in the locus on chromosome 16, two of the other genes with some evidence for a 333 334 retinol-related function (MAFTRR and LINC01229) have been shown experimentally to regulate MAF expression and are also associated with other biochemical traits like urate, further 335 supporting the role of the *Maf* family on retinol abundance in serum<sup>35</sup>. Finally, the remaining 336 locus on chromosome 2 (2:122078406-122084285) had the least interpretable functional 337 338 prioritisation results. The closest transcription start site to the lead SNP was another TF (TFCP2LI) that has broad physiological roles including in the kidney<sup>36</sup>. 339

340 We then sought to expand our scope for gene discovery beyond genome-wide significant retinol-associated loci through further integration of genetics with transcriptomics and 341 342 proteomics (Online Methods, Supplementary Tables 12-13). Firstly, we leveraged multivariate models of genetically regulated expression (GReX) to perform a transcriptome-wide (liver, 343 whole blood, adipose, small intestine, pancreas, and breast mammary tissue) and proteome-344 wide (plasma) association study (TWAS/PWAS) of circulating retinol. Tissues for the TWAS 345 346 were selected based on prior knowledge of retinol biology and the results of the partitioned heritability analyses (Online Methods), whilst plasma was the only relevant tissue available for 347 348 PWAS. After applying multiple-testing correction to the TWAS and PWAS individually (FDR < 0.05) and testing whether there was a shared causal variant via colocalisation [Posterior 349 probability (*PP*) of a shared causal variant (H4),  $PP_{H4} > 0.8$ ], we identified strong evidence of 350 four additional retinol-associated genes outside of genome-wide significant loci (at least +/- 1 351 352 megabase away). These were as follows: MLXIPL, which binds to carbohydrate response elements to regulate triglycerides<sup>37–39</sup>; *GSK3B*, a gene that encodes a member of the glycogen 353 synthase kinase family involved in metabolism and glycaemic homeostasis<sup>40</sup>; the tankyrase 354 gene (TNKS) implicated in processes like Wnt signalling<sup>41</sup>; and INHBC, part of the inhibin 355 family of proteins with important endocrine functionality<sup>42</sup>. Genetically predicted mRNA 356 357 expression of MLXIPL in adipose, pancreas, and breast mammary tissue was inversely associated with circulating retinol levels. Conversely, TWAS analyses revealed that genetically 358 359 predicted expression of GSK3B and TNKS was positively associated with circulating retinol levels. Finally, genetically predicted plasma protein expression of INHBC showed a positive 360 361 correlation with retinol levels ( $Z_{PWAS} = 4.72$ ). We then used a more conservative approach whereby finemapped variants that influence protein expression (pQTLs) were used as 362 363 instrumental variables (IV) to estimate the causal effect of plasma proteins on retinol using 364 Mendelian randomisation (MR, Online Methods, Supplementary Table 14). We applied the 365 same filters to the results (FDR < 0.05 and  $PP_{H4} > 0.8$ ). These analyses further supported that upregulated INHBC likely increases serum retinol, with each SD increase in plasma protein 366 expression associated with a small but highly statistically significant [0.05 per SD in 367 expression, 95% CI: 0.03, 0.07] impact on circulating retinol. In line with expectation, pQTL-368 MR, and subsequent colocalisation, further genetically validates that elevated RBP4 protein 369 abundance correspondingly increases serum retinol with somewhat large effect (0.6 [95% CI: 370 0.48, 0.72] SD in retinol per SD in plasma RBP4 expression). There was also evidence that 371 RBP4 protein expression and retinol colocalise under the hypothesis of a single causal variant 372  $(PP_{H4} = 1)$ . Considering the eight genes prioritised in this and the previous section (*RBP4*, 373

374 *GCKR*, *FOXP2*, *TTR*, *MLXIPL*, *GSK3B*, *TNKS*, *INHBC*), we found that these genes exhibited 375 upregulated expression in the liver ( $P_{Adjusted} < 0.05$ ) upon analysing data from 54 GTEx tissues. 376 This further consolidates the salience of hepatic processing to genetic influences on circulating 377 retinol abundance. Pathway analyses of these genes demonstrated that they were enriched 378 amongst factors involved in carbohydrate metabolism (Supplementary Table 15).

379

# 380 Wide-ranging evidence of causal effects of retinol across the human clinical phenome

381 The role of retinol in human health and disease has been of long-standing interest. However, 382 most evidence has been observational, limiting the ability for causal inference. Moreover, randomised controlled trials (RCT) of interventions like retinol supplementation and synthetic 383 384 retinoids have only been performed for a small fraction of the traits implicated through observational studies. We sought to increase our understanding of causal effects of retinol on 385 human health by leveraging genetic variants associated with retinol uncovered in this study as 386 IVs. Given certain assumptions are met, these genetic proxies of retinol can be utilised to 387 estimate causal effects of circulating retinol at scale using Mendelian randomisation (MR) 388 389 (Online Methods). Firstly, we utilised a single IV in RBP4 (rs10882283), as this gene has a 390 clear and unambiguous association with circulating retinol levels, and therefore, is less likely 391 to be prone to horizontal pleiotropy than other retinol-associated loci. We do caution, however, that RBP4 does exert some other functionality that may not be directly related to retinol 392 393 transport<sup>43</sup>, although this gene is still likely the best available single IV associated with 394 at genome-wide significance. We utilised this circulating retinol RBP4 IV 395 (METSIM+INTERVAL meta-analysis effect size) to estimate the effect of retinol on over 396 19,500 outcomes in the IEUGWAS database (IEUGWASdb, Online Methods, Supplementary 397 Table 16). After multiple-testing correction (FDR < 0.01), retinol was found to putatively exert 398 causal effects on outcomes including several lipid traits, leukocyte counts (total leukocytes and 399 neutrophils), reticulocytes, optic disc area, and resting-state connectivity of a functional MRI 400 (fMRI) derived network edge. For instance, each SD in circulating retinol was associated with a -0.1 SD [95% CI: -0.14, -0.06] decrease in leukocyte count, whilst this unit retinol increase 401 402 was estimated to increase optic disc area by 0.22 SD [95% CI: 0.12, 0.32]. We further interrogated a representative subset of these associations using colocalisation to test if the 403 404 signals are driven by a shared causal variant in *RBP4* (Supplementary Table 17). Colocalisation 405 strongly supported that the effect of circulating retinol on leukocyte count, optic disc area and 406 the edge in the fMRI network arises from a shared causal variant in RBP4. In contrast, the effect of retinol on lipids through RBP4 was shown to likely arise from linkage due to the 407

proximal gene *FFAR4* that encodes a free-fatty acid receptor. Therefore, the lipid findings most
likely do not represent a causal impact of circulating retinol, at least through *RBP4*, but rather
the influence of *FFAR4*.

411

412 To boost power for discovery of causal retinol effects, we then utilised all independent (LD  $r^2$ < 0.001) genome-wide significant SNPs as IVs (Online Methods). Firstly, we used the inverse-413 414 variance weighted estimator with multiplicative random effects (IVW-MRE) to estimate the 415 effect of retinol on IEUGWASdb outcomes for which at least six of the IVs were available (> 416 17,000 outcome phenotypes). There was moderate positive correlation between the IVW-MRE and single *RBP4* estimates across all traits tested (r = 0.43, Supplementary Figure 4). Whilst 417 well powered, the IVW-MRE assumes all IVs are valid, which is unlikely in practice. 418 Therefore, we developed a pipeline to prioritise the most confident causal relationships that 419 survive multiple-testing correction considering the IVW-MRE estimates (FDR < 0.01, Online 420 421 Methods, Figure 2A, Supplementary Tables 18-20). This was comprised of three tiers, with Tier #1 being the highest level of evidence. Retinol/outcome pairings that were assigned a tier 422 423 had to exhibit no significant heterogeneity between IV-outcome effects, a non-significant MR-Egger intercept (which screens for unbalanced pleiotropy), and not be driven by a single IV. 424 425 Four additional MR methods with differing assumptions were then applied in this study (Online 426 Methods). From the trait pairings that passed the above heterogeneity and pleiotropy filters, 427 Tier #1 traits were those for which all five methods were statistically significant, whilst Tier #2 traits had 4/5 significant methods, and Tier #3 3/5 methods significant. There were no Tier 428 429 #1 retinol/outcome trait pairings, but several Tier #2 and Tier #3 trait pairings (Figure 2B-C), with all of them directionally consistent with the estimates from the single *RBP4* IV, supporting 430 431 their validity. Broadly, we found that retinol increased body fat related measures, resting-state fMRI connectivity of several network edges, as well as food consumption phenotypes related 432 to carbohydrates. Retinol also exhibited evidence of a relationship with the cortical thickness 433 and surface area of several brain regions, as well as microbiome composition and keratometry 434 435 measurements. These results were dominated by continuous traits, for which we are better 436 powered, however, there were some binary traits assigned Tier #2 or Tier #3 evidence. Specifically, retinol was associated with decreased odds of tuberculosis sequalae and 437 coxarthrosis (arthrosis of the hip), whilst it was associated with increased odds of non-specific 438 skin eruptions, adverse asthma/COPD medication effects, and dental problems. We caution 439 440 that all these inferred associations require further investigation, and should be treated with requisite caution, as reviewed elsewhere<sup>19,44,45</sup>. A consideration of this approach that leverages 441

multiplicative random effects with relatively few IVs (< 10), is the potential influence of residual standard errors below 1 on the estimation of the IVW standard errors. We see some evidence of this impact on the IVW-MRE estimates for Tier #2 and Tier #3 traits – as these traits exhibit no significant heterogeneity between IV estimates. Specifically, whilst all fixed effect IVW results are still highly statistically significant for these traits, they have larger standard errors than the IVW-MRE, indicative of residual standard errors < 1. This is a function of the MRE not scaling the standard error of the IVW by the model's residual standard error like in the fixed effects model. We discuss this further in the supplementary text and in supplementary figure 5. However, these issues only impact the *P*-value of the IVW-MRE relative to that of the fixed effects, and Tier #2/Tier #3 traits still exhibit non-zero evidence across multiple methods and no indication of a single IV driving the association. Moreover, using instead a fixed effects IVW estimator as the primary test for trait pairings with no heterogeneity (Cochran's O P < 0.05) yields similar outcomes being prioritised as most statistically significant after FDR correction (Supplementary Text). It also important to consider when interpreting these estimates that MR approaches are only interpretable under the assumptions they make, and as a result, any potential causal relationship reported here requires further validation, ideally using a randomised control trial design. 

# **a** 476



508 Figure 2. Estimated causal effects of circulating retinol across the human clinical phenome.
509 (a) Prioritisation pipeline overview for retinol causal estimates [inverse-variance weighted

510 estimator with multiplicative random effects (IVW-MRE)] that survive multiple-testing correction (FDR < 0.01). These estimates are subjected to tests for heterogeneity and 511 512 pleiotropy (Online Methods), with a tier then assigned based on how many of the five Mendelian randomisation (MR) methods applied are at least nominally statistically significant. 513 514 In panels (**b**) and (**c**), the left-hand plot denotes the Z-score (beta/SE) from the MR IVW-MRE 515 estimates. Positive Z scores denote a positive IVW-MRE estimate of the effect of circulating 516 retinol on that trait, and vice vera. The traits are coloured by their broad phenotypic category. 517 The right-hand plot visualises the Z score using the IVW-MRE model verses that of the MR 518 estimate using the RBP4 IV alone (Wald Ratio). The dotted lines approximately represent nominal statistical significance (P < 0.05). In panel (**b**), just tier #2 traits are plotted (Online 519 520 *Methods*), whilst panel (c) plots both tier #2 and tier #3 traits.

521

522 We hypothesised that the putative effect of retinol on body fat could be one explanation for its relationship in this study to brain phenotypes beyond a direct effect of retinoid signalling, 523 particularly given that obesity and adiposity have been linked with MRI related indices<sup>46</sup>. 524 However, using IVs for body fat percentage, we did not find any strong evidence that it is 525 526 causally related to any of the retinol-associated brain regions (Supplementary Table 21), 527 suggesting a direct effect of retinol on these regions/networks or a relationship induced through some other unobserved confounder. Reverse causality for these Tier #2 and Tier #3 exposures 528 was then also considered, although for binary traits this should be treated purely as a test of the 529 null hypothesis given the difficulties in using binary traits as IVs<sup>47</sup>. There was no strong 530 531 evidence for reverse causality of any of these traits (Supplementary Table 22). One exception 532 to this was in relation to expression of the protein PEAR1, for which there was very nominal 533 evidence of bidirectional effects.

534

535 A limitation of the above phenome-wide analyses is that the multiple-testing burden that arises from the inclusion of over 17,000 traits may obscure retinol effects on binary disease 536 phenotypes, as these are usually less powered than GWAS of continuous traits. To overcome 537 538 this, we also applied the above pipeline using all retinol IVs to 1141 binary endpoints with at least 1000 cases in FinnGen release 8 (not featured in IEUGWASdb), allowing a phenome-539 540 wide analysis of electronic health record derived binary outcomes. There were eight disease phenotypes that retinol was associated with after multiple testing correction (Figure 3A, FDR 541 < 0.01), which increased to 19 with an exploratory FDR < 0.1 threshold (Supplementary Table 542 23). After applying the above pipeline to these results that considers heterogeneity, pleiotropy, 543

and consistency across MR methods, there were four disease endpoints with Tier #3 evidence (Figure 3B, Supplementary Table 24). Specifically, retinol was estimated to increase the odds of congenital malformations of the heart and great arteries, whilst it was protective for type 2 diabetes with coma and inflammatory liver disease. As these traits had tier #3 evidence, there was some inconsistency in the strength of the results across different MR methods, and therefore, these relationships should be interpreted cautiously. One of the most active areas of research in retinol epidemiology is the relationship between retinol and cancer risk<sup>48</sup>. The estimated effect of circulating retinol on the odds of any malignant neoplasm was not significantly different than one - OR = 0.97 [95% CI: 0.91, 1.04], P = 0.423 (Supplementary Figure 6). However, there was some indication of a protective effect of retinol on squamous non-small cell lung cancer, which approached the threshold for statistical significance after FDR correction - OR = 0.64 [95% CI: 0.51, 0.80],  $P = 8.19 \times 10^{-5}$ , q = 0.01. There was also some data to support retinol having effects on other respiratory neoplasm endpoints (Supplementary Figure 6). Given previous observational evidence that retinol is protective for lung cancer<sup>48</sup>, as well as some data supporting the use of synthetic retinoids like bexarotene in lung neoplasms<sup>49</sup>, this relationship warrants further exploration. 

medRxiv preprint doi: https://doi.org/10.1101/2023.08.07.23293796; this version posted August 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .





endpoints in the Finnish population. (a) Volcano plot denoting the phenome-wide MR 611

612 estimates of retinol (SD units) and the log odds of each binary endpoint in FinnGen release 8. *The x-axis denotes the log odds (IVW-MRE), whilst the y-axis denotes the -log<sub>10</sub> P-value of the* 613 MR estimate. The dotted horizontal line is approximately equivalent to the magnitude of P-614 value that is estimated at an FDR of 1%. Categories highlighted by a blue box on the legend 615 616 indicate that an endpoint in that category survived multiple-testing correction. (b) Retinol effects on binary FinnGen endpoints after multiple-testing correction (FDR < 0.01) with the 617 strongest evidence from all phenotypes tested based on heterogeneity, pleiotropy, and 618 consistency across MR estimators (Tier #3, Online Methods). Each panel denotes the effect 619 620 sizes (odds ratio with 95% confidence intervals per SD in circulating retinol) for the IVW-MRE, the IVW with fixed effects (IVW-FE), the MR-Egger, Weighted median, and Weighted 621 622 Mode, respectively.

623

We also investigated evidence for bidirectional effects involving these Tier #3 traits that retinol is genetically predicted to influence. As described above, using binary traits as exposures in MR should be treated with suitable caution and are often underpowered. The use of either genome-wide significant or suggestively significant SNPs ( $P < 1 \times 10^{-5}$ ) as IVs did not indicate evidence of reverse causality of these diseases to retinol (Supplementary Table 25). However, given some of the statistical limitations of these analyses, such effects warrant further consideration.

631

#### 632 Genetic evidence that lipids and kidney function influence circulating retinol

It is also clinically valuable to understand exposures and diseases that impact circulating retinol 633 634 abundance. To explore this in greater detail, we leveraged retinol as an outcome trait in MR analyses. We utilised a diverse range of thousands of continuous and ordinal phenotypes from 635 IEUGWASdb as exposures in a similar pipeline described above (Online Methods). Several 636 lipid species were demonstrated to putatively influence retinol abundance after multiple-testing 637 638 correction (FDR < 0.01, Figure 4A, Supplementary Table 26); for example, triglycerides were 639 implicated to increase circulating retinol whilst cholesteryl ester related traits decreased circulating retinol. We also saw a positive effect of the frequency of solarium and sun lamp use 640 on retinol, which may arise from behavioural related mechanisms. Furthermore, our findings 641 642 suggest that increased retinol levels are associated with a susceptibility-weighted MRI measure in the left putamen, called T2\*. T2\*, reflecting magnetic susceptibility relative to tissue water, 643 can be influenced by factors such as iron and calcium content. This association may also be 644 influenced by behavioural or other pathways that warrant further investigation. 645

646 After applying the same tiering system used for retinol as an exposure, we observed Tier #1 evidence strongly supporting a causal effect of creatinine on circulating retinol. This 647 relationship is biologically plausible and likely represents an association with kidney 648 function<sup>50,51</sup>. Due to the biological complexity of lipid traits, we observed significant 649 heterogeneity between IV effects, and as a result, they were not assigned a tier in our analysis. 650 651 However, the effect of triglycerides on increasing circulating retinol levels is consistent with 652 established knowledge of retinol biology, as well as this study implicating two genes that are mechanistically confirmed to impact triglycerides (GCKR and MLXIPL). We then leveraged 653 654 the CAUSE model to distinguish causal effects of creatinine on circulating retinol from correlated pleiotropy that may arise between these two traits due to the extensive polygenicity 655 of creatinine<sup>52</sup>. We found that a model that includes a causal effect of creatinine on retinol was 656 more parsimonious than a model of pleiotropy alone ('sharing model') through comparison of 657 these models using the Bayesian expected log pointwise posterior density (ELPD) method 658 (Supplementary Figure 7,  $\Delta$ ELPD<sub>Sharing vs Causal</sub> = -4.34,  $P = 8.9 \times 10^{-3}$ ). Given that IVs for 659 creatinine could plausibly act through lipid species like triglycerides to influence circulating 660 661 retinol, we then constructed multivariable MR (MVMR) models that estimated the creatinine to retinol relationship conditioned on high density lipoprotein (HDL), low density lipoprotein 662 663 (LDL), and triglycerides (Online Methods). While there was some evidence that the effect of 664 creatinine on retinol could arise due to triglycerides, there was also evidence to suggest an independent effect of both triglycerides and creatinine on increasing circulating retinol, 665 depending on the modelling parameters used (Figure 4B, Supplementary Text). In addition to 666 investigating the causal effects of exposures on retinol, we also examined the possibility of 667 bidirectional effects. We found very weak evidence that retinol has a negative effect on 668 creatinine (P = 0.023), but there was no significant evidence to suggest bidirectional 669 relationships between retinol and the other implicated exposures. 670



680 Figure 4. Exploring the causal effects of continuous exposures on circulating retinol. (a) Exposure traits that demonstrated a significant causal estimate (IVW-MRE) on circulating 681 682 retinol after multiple-testing correction (FDR < 0.01). Traits are coloured relative to their broad phenotypic category. (b) Multivariable MR (MVMR) models investigating the effect of 683 684 creatinine and major lipid species on circulating retinol. Each panel represents the results from a different MVMR model (each with different underlying assumptions (Online Methods)). 685 686 *The exposure – retinol relationship plotted is conditional on the three other traits in the model.* 

687

688 Finally, we explored pharmacological agents and molecular perturbagens that may influence circulating retinol (Online Methods). Considering the novel genes prioritised in this study with 689 an assigned direction of expression (TWAS/PWAS, pQTL MR), it was found that GSK3B is a 690 drug-target known to be inhibited by lithium and related compounds. This may be of clinical 691 692 interest as it suggests that lithium, utilised as a therapy in mood disorders, may decrease circulating retinol via its inhibition of GSK3B given that genetically predicted expression of 693 694 this gene was positively associated with retinol. We then employed computational signature mapping to further characterise pharmacological agents related to retinol (Online Methods). 695 696 However, these analyses did not yield any compounds for which the *in vitro* transcriptomic 697 signature significantly matched or opposed genetically predicted expression associated with 698 retinol after multiple-testing correction (Supplementary Table 27). We then considered 699 perturbagen signatures aggregated to biological pathways or overall mechanisms of action (MOA) groups of compounds (Online Methods). After multiple-testing correction (FDR < 700 701 0.05), there were 13 gene-set based perturbagen signatures that were significantly similar to the directionality of genetically predicted expression associated with retinol (Supplementary 702 703 Table 28). For example, the expression signature of compounds in the HDAC inhibitor MOA 704 opposed expression genetically predicted to increase serum retinol. This can be interpreted as 705 while no single HDAC inhibitor was significantly associated with retinol, there was at least 706 some evidence for the overall relationship with this MOA. This accords with the suggested effect of HDAC inhibitors like valproic acid on downregulating expression of RBP4<sup>53-55</sup>, a 707 708 gene not included in the signature mapping analyses given the large effect of its encoded 709 protein on retinol.

- 710
- 711
- 712

#### 713 Genetically proxied retinol can identify individuals outside of the normative range of

#### 714 circulating retinol for a given age

715 We were also interested in evaluating the performance of a genetically proxied index of circulating retinol, that is, a circulating retinol polygenic score (PGS). The independent 716 717 TwinsUK cohort was utilised to tune and evaluate retinol PGS (Online Methods). We used several methods to evaluate the performance of a retinol PGS in this cohort. Firstly, we test 718 719 different retinol PGS configurations in a random selected training subset of the model (70% of cohort), using a linear mixed model to account for relatedness between the twin pairs. The best 720 721 performing retinol PGS configuration in the training subset explained approximately 2.12% of 722 the phenotypic variance of retinol when applied to the remaining 30% of the cohort (mean 723 variance explained across three retinol measurement timepoints). We also found similar performance when applied to each subset of twin pairs (Supplementary Table 29). A limitation 724 725 of this approach for using the same cohort for tuning and testing the retinol PGS is that the estimated effect sizes may not be representative. As a result, we employed an approach to tune 726 727 weights for the PGS using the summary statistics alone. This was achieved through leveraging the principles of probabilistic finemapping to update variant weights by their posterior 728 729 probability of association (Online Methods). Due to the modest polygenicity of retinol, this 730 method upweights a small number of variants. Despite this, these scores were still significantly 731 associated with circulating retinol in TwinsUK (Supplementary Table 29).

732

Like most micronutrients, circulating retinol has been shown previously to have a complex 733 relationship with age<sup>56</sup>. However, population-level approaches investigating these effects do 734 not account for inter-individual variability. We hypothesised that normative modelling could 735 736 be used to characterise individual patterns of circulating retinol, and to evaluate the 737 contribution of genetics to these individualised effects. Normative modelling, derived from the 738 application of growth charts in paediatric medicine, aims to estimate normative reference ranges of variation in the population (e.g., of circulating retinol) based on age and/or other 739 relevant variables. Here, we established reference ranges for circulating retinol as a function of 740 741 age using generalised-additive models for location, scale, and shape (GAMLSS) frameworks 742 in the TwinsUK dataset (Online Methods, Supplementary Text). These models were 743 constructed in the full cohort, as well as in one twin subset only for comparison. Briefly, this involved identifying the optimal distribution for the GAMLSS model using all samples, 744 745 followed by splitting the data into two partitions. One partition was utilised to estimate centiles 746 (5<sup>th</sup>, 25<sup>th</sup>, 50<sup>th</sup>, 75<sup>th</sup> and 95<sup>th</sup>), and the left-out subjects were benchmarked against this reference

chart to determine the position of their individual retinol measurement (Online Methods). This
process was then repeated using the opposite subject allocation. An individual's retinol level
was classified as infra-normal if their measured retinol fell below the 5<sup>th</sup> percentile for their
age, and as supra-normal if their retinol value exceeded the 95<sup>th</sup> percentile for their age.

751

752 We then investigated the extent to which retinol PGS was associated with these individual 753 profiles of circulating retinol with respect to age (Supplementary Table 30). By way of 754 example, we report results forthwith from the more conservative modelling approach which 755 only used one half of the twins. Retinol PGS was at least nominally significantly associated with supra and infra-normal deviations except for supra-normal deviations at the first (youngest 756 757 visit) for which there was only a trend observed (Supplementary Figures 8-9). For example, at the second visit each SD in retinol PGS was associated with an approximately 70% [95% CI: 758 759 23%, 136%] increase in the odds of exhibiting supra-normal retinol levels for a given age relative to all remaining participants, whilst conversely reducing the odds of displaying infra-760 761 normal levels by approximately 37% [95% CI: 12%, 55%]. These data suggest that genetics is 762 a non-zero contributor to circulating retinol levels that fall outside the normative range for a 763 given age. In future, a normative modelling approach could be utilized to examine additional 764 factors, including dietary intake, as well as the interplay between genetics and other influences, that might contribute to individualized deviations in retinol levels relative to the population 765 766 benchmarks.

767

#### 768 DISCUSSION

769 We conducted the largest GWAS of circulating retinol to-date, revealing important novel insights into genetic influences on this trait. The sample sizes in this study facilitated the first 770 771 published estimate of SNP heritability for circulating retinol, plausibly between 5-10%. 772 However, the large standard errors accompanying these estimates reinforces that greater 773 sample sizes are still needed. Moreover, we were able to uncover confident genetic signals 774 associated with retinol at genome-wide significance outside of the RBP4:TTR transport complex. The gene prioritisation pipeline applied both within and beyond genome-wide 775 776 significant loci prioritised eight genes with high-confidence for a role in retinol biology. These 777 genes were highly expressed in the liver and overrepresented amongst biological pathways including carbohydrate metabolism. The liver is known to be the key organ responsible for 778 retinol storage and processing<sup>1</sup>, which is represented strongly by the genetic data in this study. 779 780 Further, the prioritised genes assigned as overrepresented in the *regulation of carbohydrate* 

781 metabolic process pathway (GCKR, GSK3B, and MLXIPL1) are all broadly known to be related 782 to hepatic energy metabolism. As lipids are directly mechanistically linked to retinol 783 absorption, storage, and delivery<sup>1,3</sup>, it is plausible that the varied metabolic roles of these genes converge on changes in the abundance of different lipid species. The role of lipids in circulating 784 785 retinol abundance is also highlighted by our Mendelian randomisation analyses. However, it is still likely that glycaemic homeostasis may impact circulating retinol via mechanisms not 786 787 directly linked to lipid biology; for example, expression of the insulin-controlled glucose transporter GLUT4 is postulated to be related to RBP4 protein levels<sup>57</sup>. In summary, our results 788 789 suggest that the most identifiable common variant influences on circulating retinol are either 790 mediated through direct effects on transport or metabolic factors, particularly related to lipids. 791 We also prioritised genes like FOXP2 for which a mechanistic relationship to retinol is less inherently clear. Our analyses of transcriptomic correlates of FOXP2 supported the immense 792 793 biological pleiotropy associated with this transcription factor, reinforcing its significance outside of its traditionally conceived association in the literature with neurological phenotypes 794 795 like language. Work is now needed to disentangle the mechanisms which specifically underlie 796 this relationship between FOXP2 and circulating retinol that were infer from these genetic 797 findings.

798

799 Our study also represents a significant advancement as it is the first to perform a highthroughput, hypothesis free, analysis investigating the potential causal effects of retinol across 800 a wide range of human clinical phenotypes using Mendelian randomisation. This work 801 recapitulated known influences of retinol on ophthalmological measures<sup>58</sup>, the innate and 802 adaptive immune response<sup>59</sup>, and congenital heart malformations<sup>60</sup>. However, we also 803 804 uncovered some more novel relationships that may be of direct clinical relevance. We highlight 805 forthwith the example of circulating retinol being genetically predicted to impact the thickness 806 and surface area of several brain regions, as well as indices of brain connectivity. Retinoic acid, 807 a downstream metabolite of retinol, is considered one of the most intrinsic central nervous system signalling molecules, particularly as it exerts control over processes like neuronal 808 differentiation *in utero* and adult neurogenesis, as reviewed elsewhere<sup>2</sup>. It is, therefore, logical 809 that retinol would plausibly influence brain structure and connectivity throughout the lifespan. 810 811 However, the regions implicated in this study require further examination with respect to their clinical significance. By way of example, we associated increased circulating retinol with a 812 813 reduction in thickness in the right rostral anterior cingulate cortex. This cortical region has been 814 identified by a large international mega-analysis from the ENIGMA consortium to exhibit

increased thickness in individuals with the neuropsychiatric disorder schizophrenia compared 815 to controls<sup>61</sup>, suggesting a potential protective effect of retinol in this region with respect to 816 schizophrenia. This accords with previous evidence linking retinoids to schizophrenia<sup>2,62</sup>. It is 817 known clinically that both retinol deficiency and toxicity can have harmful neurological 818 819 effects, highlighting the complexity of the relationship of retinol to the brain throughout the human lifespan. This complexity is also seen with synthetic retinoids. For instance, isotretinoin 820 821 (13-cis retinoic acid), indicated for conditions like acne, has been shown to have opposing effects on adult neurogenesis relative to all-*trans* retinoic acid and putatively increases the risk 822 of suicide<sup>63,64</sup>, although evidence for this association is mixed<sup>65</sup>. Conversely, another synthetic 823 retinoid, bexarotene, with different receptor affinities to isotretinoin, has demonstrated some 824 promise as a potential adjuvant to antipsychotics in schizophrenia<sup>66</sup>. Future work should 825 attempt to understand these relationships with greater fidelity by investigating genetic 826 influences on other retinoids beyond retinol, as well as how tissue-specific abundance can 827 differ from what circulates in serum<sup>67</sup>. Emerging methods for non-linear Mendelian 828 randomisation would also be useful in this context given that retinol often exerts dose 829 dependent effects<sup>68</sup>. The causal estimates generated in this study also need to be treated with 830 831 appropriate caution due to the limitations of MR and require further validation in study designs 832 that can enable causal inference, such as randomised control trials. As reviewed previously<sup>18,19,69</sup>, MR tests are only unbiased when their assumptions are plausibly satisfied, 833 834 which is why we implement a suite of different methods and sensitivity analyses with quite distinct underlying assumptions in this study. Genetic estimates on circulating retinol used as 835 836 IVs could also be confounded by factors including uncontrolled population stratification, selection bias, and measurement error. In summary, we provide a large resource to the literature 837 838 of putative effects of circulating retinol across the human clinical phenome that will be 839 informative for future investigation of this trait.

840

Finally, we make some recommendations for future GWAS of retinoid molecules. An 841 important limitation of our analyses is that we only investigated genetic effects on circulating 842 843 retinol, rather than retinol availability within target tissues. Given the complexities of retinol homeostasis, it is plausible that genetic effects on factors like retinol entry into the cell (e.g., 844 845 STRA6 receptor) and esterification for storage (e.g., lecithin retinol acyltransferase) are obscured when considering only retinol present in serum or plasma. Therefore, future studies 846 847 should attempt to measure retinol abundance in different tissues from genotyped samples, although this will pose a challenge in terms of obtaining sufficient sample sizes. Moreover, it 848

would be of interest to characterise the genetic overlap between effects on retinol versus other
retinoids like retinaldehyde and all-*trans* retinoic acid. Despite these limitations, and the need
for concerted efforts to collect more data, we believe this study demonstrates the value in

- 852 conducting retinol GWAS to both better characterise retinoid associated biology and its clinical853 significance.
- 854

# 855 ONLINE METHODS

## 856 Study cohorts

The proceeding section outlines the datasets included in the genome-wide meta-analysis ofcirculating retinol, as well as the replication cohort.

859

860 INTERVAL

The largest constituent cohort of the meta-analysis was drawn from the INTERVAL study, 861 comprised of recruited blood donors from the United Kingdom<sup>70</sup>. Retinol abundance was 862 measured from plasma using the high-throughput metabolomics platform DiscoveryHD4® 863 (Metabolon, Inc., Durham, USA), as outlined in the supplementary text. Briefly, after 864 adjustment for various technical/biological confounders and outlier effects, residualised 865 866 plasma retinol was inverse-rank normal transformed before association testing. Whole-genome sequencing of this cohort was performed as described elsewhere<sup>71</sup>. A GWAS of the normalised 867 residuals was performed in HAIL via multiple-linear regression adjusted for INTERVAL 868 metabolon batch and 10 genetic PCs<sup>72</sup>. The final GWAS sample size was 11,132 European 869 870 ancestry participants.

871

# 872 *METSIM*

Plasma retinol was also measured using the DiscoveryHD4<sup>®</sup> high-throughput platform in a 873 874 recent metabolome-wide GWAS of the METSIM (Metabolic Syndrome in Men) study<sup>73</sup>. The METSIM cohort consists of middle-aged men recruited from Northern Finland between 2005-875 2010<sup>74</sup>. As described by Yin *et al.*<sup>73</sup>, METSIM participants were genotyped using the Human 876 OmniExpress-12v1 C BeadChip and imputed using a custom METSIM panel of whole 877 genome-sequenced participants in the study. A linear mixed model implemented in EPACTS 878 v.3.2.6 was then leveraged to perform GWAS on residualised retinol, subjected to inverse-rank 879 transformation after adjustment for technical and biological confounders. The final GWAS had 880 881 a sample size of 6136 METSIM participants (European ancestry).

882

#### **883** *ATBC+PLCO*

The largest previous dedicated GWAS of circulating retinol from 2011 was also included in 884 this study<sup>22</sup>. This GWAS comprised data from two studies that measured serum retinol: the 885 Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, a Finnish randomised 886 887 control trial of beta-carotene/alpha-tocopherol supplementation for cancer prevention<sup>75</sup>, and the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, a United States 888 889 trial of cancer screening effectiveness<sup>76</sup>. The inclusion criteria, measurement of serum retinol, and genotyping have been outlined by Mondul et al.<sup>22</sup>. Briefly, ATBC/PLCO samples were 890 genotyped using the Illumina HumanHap550/610 arrays and imputed to the HapMap Central 891 European reference panel, whilst serum retinol concentrations were estimated using reversed-892 893 phase liquid chromatography. The retinol GWAS (N=5006) was performed in R (version 2.10.1) using multiple linear regression adjusted for age at sample collection, SNP derived PCs, 894 cancer status, serum cholesterol, and body mass index. The retinol units for the GWAS effect 895 sizes were in natural log transformed µg/L. A limitation of using summary statistics from this 896 897 study is that only < 600,000 variants were available for inclusion in the GWAS, as was common 898 at the time before more recent advances in imputation pipelines that result in larger post-899 imputation yield. Therefore, to increase the number of variants available for meta-analysis, we 900 applied a summary statistics-based imputation procedure to boost the number of variants 901 available for meta-analysis. After harmonisation with the 1000 genomes phase 3 reference 902 panel, we applied Gaussian summary statistics imputation (ImpG) as implemented by the FIZI v0.7.2 python package (https://github.com/bogdanlab/fizi) with the default window size of 250 903 904 kb<sup>77</sup>. The ImpG model leverages the assumed Gaussian distribution of GWAS Z scores with mean zero and variance that arises due the LD-induced correlation between variants. As 905 906 outlined elsewhere<sup>77</sup>, Z scores of unobserved (imputed) variants can be estimated given the LD 907 correlation matrix derived from the reference panel, along with a metric of imputation accuracy 908  $(R^2)$  using the conditional variance. We retained only confidently imputed variants  $(R^2 > 0.8)$ .

909

910 *TwinsUK* 

We performed a serum retinol GWAS in the TwinsUK cohort to serve as a replication dataset.
High-throughput metabolomics profiling in this cohort has been described extensively
elsewhere<sup>78</sup>. TwinsUK is a prospective population-based study of mostly female twin pairs
which has been profiled using a variety of multiomic technologies<sup>79</sup>. As outlined by Shin *et al.*,
genotyping was performed with a combination of Illumina arrays (HumanHap300,
HumanHap610Q, 1M-Duo and 1.2MDuo 1M)<sup>80</sup>. This was followed by imputation to the 1000

917 genomes phase reference panel after quality control and retaining individuals of predominantly European ancestry after PCA. We retained physically genotyped variants and those with 918 moderate imputation accuracy for GWAS ( $R^2 > 0.3$ ) in 5654 samples. Our strategy for GWAS 919 920 in this cohort given the limited sample size with measured retinol available was to split the 921 twin pairs into two separate cohorts and ensure individuals in each sub-cohort were unrelated. Relatedness testing in both sub-cohorts containing one of the two possible twin pairs was 922 923 performed separately using KING as implemented by plink2 (PLINK v2.00a3LM AVX2 Intel), with one participant from third-degree relative or greater pairs randomly removed<sup>81,82</sup>. 924 Kinship estimation via KING was performed for autosomal variants physically genotyped on 925 the array, with a MAF > 0.05, outside of regions of long-range LD like the MHC<sup>83</sup>, and in 926 relative linkage equilibrium ( $r^2 < 0.05$ ). PCA was then applied in each sub-cohort using plink2 927 to calculate eigenvectors for use as downstream covariates. Retinol was measured from 928 929 samples at three timepoints. The mean age of participants at each timepoint was 51.5 (SD = 8.41), 58.6 (SD = 8.38), and 64.7 (SD = 8.41), respectively. There were only a very small 930 number of males in this cohort ( $\sim 3\%$ ), so only females were retained for further analysis (N = 931 1696) due to this imbalance in sex composition. After merging with the genotyped split twin 932 933 cohorts, as described above, there were up to 916 and 717 genotyped participants with 934 measured retinol at three timepoints in each subset, respectively. Six GWAS were performed: in each sub-cohort (one or two), multiple linear regression was utilised to test the additive effect 935 936 of each variant on measured retinol at one of the three measured time-points covaried for age, five SNP derived PCs, and metabolomics batch. These GWAS was performed using the --glm 937 938 flag in plink2, resulting a 9,051,192 by three matrix of estimated retinol effect sizes for both 939 sub-cohorts.

940

# 941 Genome-wide meta-analyses

942 We conducted genome-wide meta-analysis of common variants (MAF > 0.01) using METAL (version March 2011), followed by a rare variant (MAF < 0.01) meta-analysis also with 943 METAL. The METSIM and INTERVAL cohorts were integrated for the primary meta-analysis 944 945 as they both had expansive genome-wide coverage of common and rare variants. A sample size weighted meta-analysis of Z scores (Stouffer's method) was utilised for this purpose. We also 946 947 conducted the METSIM+INTERVAL meta-analysis via an inverse-variance weighted estimator with fixed effects to estimate the effect sizes of effect alleles in SD units of plasma 948 949 retinol given this was the unit of both the METSIM and INTERVAL GWAS, as well as both studies using the same Metabolon Inc. platform for metabolite quantification. Heterogeneity 950

between the studies was assessed using Cochran's *Q* test. We then conducted a meta-analysis
with fewer available variants that also included ATBC+PLCO using Stouffer's method (as the
unit for this GWAS differed from METSIM and INTERVAL). This larger sample-size metaanalysis was also restricted to common variants as there was very limited rare variant coverage
in ATBC+PLCO.

956

957 The FUMA v1.4.1 (Functional Mapping and Annotation of Genome-Wide Association Studies) platform was utilised to annotate variants, define lead SNPs, and infer loci boundaries 958 for genome-wide significant signals  $(P < 5 \times 10^{-8})^{84}$ . We utilised the default settings for 959 defining independent significant SNPs ( $r^2 \le 0.6$ ) and lead SNPs ( $r^2 \le 0.1$ ). LD estimation was 960 achieved using the 1000 genomes phase 3 European reference panel, with LD blocks within 961 250 kb of each other merged into a single locus. We then attempted to replicate the lead SNPs 962 963 from the eight genome-wide significant loci (METSIM+INTERVAL) in TwinsUK, as described in the previous section. Given the small sample size of TwinsUK, we sought to 964 965 ascertain if the lead SNPs were directionally consistent with the meta-analysis. This was 966 achieved by taking the mean SNP Z score across the three timepoints for the two sub-cohorts 967 of unrelated participants, with a binomial test utilised to infer whether the number of lead SNPs 968 (mean Z) that were directionally consistent was greater than chance alone (Binomial P < 0.05). 969

970 In the rare-variant meta-analysis, we annotated variants using the Functional Annotation of Variants (FAVOR) online resource<sup>85</sup>. Phenome-wide association profiles of selected variants 971 were also investigated using the pheweb browser collated from FinnGen release 8 972 (https://r8.finngen.fi/)<sup>86</sup>. Rare variants were then aggregated to genes through leveraging the 973 characteristics of the Cauchy distribution<sup>87,88</sup>. In this approach, gene-wise P values are summed 974 and then transformed to approximate a Cauchy distribution, which due to its heavy tail is 975 976 insensitive to correlations amongst the *P* values. This behaviour of the Cauchy distribution is important as covariance amongst rare variants is difficult to estimate, and therefore, this 977 approach guards against inflated type I error due to potential unknown covariance/LD between 978 979 rare variants. Code for implementing the Cauchy aggregation was adapted from 980 https://github.com/yaowuliu/ACAT.

981

#### 982 SNP heritability estimation

983 Summary statistics for the meta-analyses were 'munged' using the munge\_sumstats.py script
984 from the *ldsc* repository of scripts (<u>https://github.com/bulik/ldsc</u>) and only common (MAF >

0.05) HapMap3 variants outside of the MHC retained. SNP heritability was then estimated 985 using the LDSR model and the 1000 genomes phase 3 reference panel<sup>89</sup>. By way of 986 987 comparison, we then estimated SNP heritability using the LDAK model via the SumHer implemented in LDAK v.5.2 (https://dougspeed.com/)<sup>90</sup>. Pre-computed tagging files derived 988 989 from 2000 white British individuals in the UKBB for HapMap3 SNPs were utilised to calculate SNP heritability using the LDAK-thin and BLD-LDAK models, as described elsewhere<sup>90,91</sup>. 990 991 We also estimated partitioned SNP heritability via LDSR using a multi-tissue and cell-type panel<sup>92</sup>. 992

993

# 994 Empirical Bayes' modelling of the genetic architecture of retinol

We investigated the polygenicity of the genetic architecture of circulating retinol using an 995 Empirical Bayes' adaptive shrinkage method termed ashR<sup>93</sup>. Functions to perform this method 996 were implemented via the ashR R package v2.2-54 (https://github.com/stephens999/ashr). 997 Briefly, this approach models effect sizes, along with their standard error, as a mixture of zero 998 999 and non-zero effects. Empirical Bayes' inference is performed under the assumption that the distribution of these variant effects is unimodal, which is a realistic assumption for genetic 1000 1001 effects on complex traits. The METSIM+INTERVAL IVW meta-analysis was utilised for this 1002 as it provides an interpretable effect size and standard error for each variant (plasma SD units). In line with previous work<sup>94</sup>, we annotated each HapMap3 variant with its corresponding LD 1003 1004 score from the 1000 genomes phase 3 European reference panel, as well LD scores from the UKBB White Great British samples for comparison, and sorted these into bins of similar LD 1005 1006 scores (N<sub>Bins</sub>=1000 and N<sub>Bins</sub>=5000). The ashR Empirical Bayes' inference of the proportion of non-zero effects was undertaken in each LD score bin, followed by calculating the mean 1007 1008 across all bins. We utilised a generalised additive model to plot a smoothed trend line of the 1009 relationship between increasing LD score bin (higher LD score) and the proportion of non-zero 1010 effects.

1011

# 1012 Gene prioritisation

Gene prioritisation was performed within genome-wide significant loci, as well as outside of loci that obtained genome-wide significance. Due to the better coverage of common variants, we focused on the METSIM+INTERVAL meta-analysis for this analysis. The pipeline for prioritising putative causal genes within the eight genome-wide significant loci was adapted from a previous GWAS performed by our group<sup>95</sup>. The following criteria were utilised in this study: 1) closest transcription start site (TSS) to the lead SNP, 2) closest gene (any) to the lead

1019 SNP, 3) gene encoding retinoid transporter or enzyme in locus, 4) non-synonymous variant in locus, 5) the most statistically significant GTEx eGene [expression quantitative trait loci 1020 1021 (eQTL) signal] in locus, 6) most significant GTEx eGene in finemapped credible set for eQTL signal [posterior inclusion probability (*PIP*) > 0.1, DAP-G method]<sup>96,97</sup>, 7) strongest plasma 1022 1023 pGene [protein quantitative trait loci (pQTL) signal] drawn from finemapped pQTLs (PIP >  $(0.5)^{98}$ , 8) highest CADD score<sup>99</sup>, 9) lowest RegulomeDB score<sup>100</sup>, 10) the OpenTargets V2G 1024 predicted gene for the lead SNP<sup>101</sup>, and 11) genes physically mapped to SNPs in the 95% 1025 credible set derived from probabilistic finemapping (assuming a single causal variant such that 1026 LD did not have to be modelled)<sup>102</sup>. We used a prior variance of 0.15 to approximate Bayes' 1027 factors from variant-wise effect sizes (METSIM+INTERVAL IVW meta-analysis), in line 1028 with previous work finemapping association signals with quantitative traits<sup>103</sup>. We 1029 characterised which genes satisfied the greatest number of the above criteria on a per locus 1030 1031 basis.

1032

1033 FOXP2 was one of our confidently prioritised genes but its biological significance outside of 1034 the brain is less well understood. To investigate this, we analysed RNA sequencing data from an *in vitro* experiment that overexpressed *FOXP2* in a human osteosarcoma epithelial cell line 1035 1036 (U2OS) via transfection of wild-type FOXP2 expressing plasmids. Raw read counts from five control cell line replicates versus five plasmid transfected FOXP2 overexpression replicates 1037 were downloaded from the Gene Expression Omnibus (GEO) resource (GEO Accession: 1038 GSE138938). Data normalisation, filtration, and differential expression analyses were 1039 performed using the edgeR package version 3.34.0<sup>104</sup>. Specifically, raw counts were firstly 1040 normalised to library size and lowly expressed genes with fewer than 10 raw counts in the 1041 1042 smallest library removed via a counts-per-million thresholding approach. Data were inspected 1043 before and after the filtration step via coefficient of variation (BCV) and multidimensional 1044 scaling (MDS) plots (Supplementary Figure 10). Differential expression for each gene that survived quality control was then performed using exact tests for differences in the means 1045 between two groups of negative-binomially distributed counts. We defined a differentially 1046 expressed gene as those which survived multiple-testing correction using the Bonferroni 1047 method ( $P_{\text{Corrected}} < 0.05$ ), with three different absolute log<sub>2</sub> fold change (FC) cut-offs 1048 1049 considered:  $|\log_2 FC| > 1.5$ ,  $|\log_2 FC| > 2$ , and  $|\log_2 FC| > 5$ . The use of Bonferroni correction and 1050 large absolute FC thresholds is very conservative; however, given the volume of differentially 1051 expressed genes, and a relatively large number of replicates for a cell line experiment boosting 1052 power, we believe these strict parameters are warranted to priortise the most salient FOXP2

associated signals. The overrepresentation of each set of candidate genes amongst biological
 pathways and other ontology sets was tested using g:Profiler<sup>105</sup>.

1055

1056 To identify potential causal genes that have not reached genome-wide significance at our 1057 current sample size, we integrated the circulating retinol GWAS with genetic effects on mRNA and protein expression. Firstly, we conducted a transcriptome and proteome-wide association 1058 1059 study (TWAS/PWAS) of circulating retinol using the FUSION approach<sup>106</sup>. As outlined previously<sup>107-110</sup>, FUSION leverages models of *cis*-acting genetically regulated expression 1060 1061 (GReX) that exhibit statistically significant non-zero heritability. Variant weights from GReX models are integrated with the effect of those same variants on retinol to estimate the direction 1062 1063 of genetically regulated expression associated with increasing circulating retinol. TWAS GReX 1064 (mRNA) were estimated previously using GTEx v8 (http://gusevlab.org/projects/fusion/). We selected the following biologically informative 1065 tissues to perform TWAS based on known retinol biology or tissues that exhibited at least 1066 nominally significant (P < 0.01) enrichment of SNP heritability in the partitioned-LDSR 1067 1068 model. The selected tissues were: small intestine terminal ileum, pancreas, liver, adipose (visceral omentum), adipose (subcutaneous), breast (mammary tissue), and whole blood. It has 1069 1070 been suggested previously that TWAS signals from tissues that are less directly trait relevant can induce spurious associations, which is why we limited our hypothesis space to these 1071 1072 tissues<sup>111</sup>. Protein GReX were derived from plasma (ARIC study), as outlined elsewhere<sup>98</sup>. We applied Benjamini-Hochberg false discovery rate (FDR) correction across all TWAS Z, 1073 1074 followed by all PWAS Z. Colocalisation between GReX models and retinol was performed for 1075 all TWAS/PWAS signals that were at least nominally significant via the coloc package as 1076 implemented by FUSION (single shared variant hypothesis)<sup>103</sup>. We then considered a more conservative approach to priortise proteins for whom expression could be causally linked to 1077 circulating retinol through leveraging finemapped plasma pQTLs (PIP > 0.5, ARIC) as 1078 instrumental variables (IV) for Mendelian randomisation<sup>19,44,98</sup>. The Wald ratio method was 1079 implemented for proteins with single IVs, whilst an inverse-variance weighted estimator with 1080 fixed effects was utilised for proteins with more than 1 IV. Fixed effects were used for the IVW 1081 rather than multiplicative-random effects in this instance as no protein had > 4 IVs. The use of 1082 1083 IV based approaches for identifying trait-associated genes versus GReX has been discussed extensively elsewhere<sup>109</sup>. Colocalisation was also performed for proteins that survived FDR 1084 1085 correction. Mendelian randomisation was performed using the TwoSampleMR package v0.5.6,

1086 with IVs clumped through leveraging LD from the 1000 genomes phase 3 European reference 1087 panel to retain only independent pQTLs ( $r^2 < 0.001$ ).

1088

1089 Finally, we investigated the tissue specificity of prioritised genes from GWAS loci and the 1090 TWAS/PWAS/MR approach using FUMA. To do this, we compared the expression of these 1091 prioritised genes using a *t*-test (one-sided and two-sided) against all other available genes in 1092 GTEx v8 on a per tissue basis (54 tissues), followed by applying Bonferroni correction to these 1093 P-values<sup>84</sup>. We also conducted pathway analyses of these genes using g:Profiler with default 1094 parameters<sup>105</sup>.

1095

#### 1096 Causal inference

We developed and implemented a comprehensive pipeline to leverage this retinol GWAS to 1097 identify putative causal effects of retinol on traits across the human clinical phenome, as well 1098 as traits that causally influence retinol in the reverse direction. This was achieved using 1099 Mendelian randomisation (MR), which has been reviewed extensively elsewhere<sup>19,45,69</sup>. Firstly, 1100 we considered circulating retinol as the MR exposure. The lead SNP in *RBP4* was first chosen 1101 as a single IV to proxy circulating retinol as out of all the genes implicated in genome-wide 1102 1103 significant loci, *RBP4* has exhibits the most specificity in terms of its relationship with serum retinol. We utilised the Wald ratio method to estimate the effect of the circulating retinol 1104 1105 increasing rs10882283-A allele (METSIM+INTERVAL IVW effect size) on over 19,000 outcomes in the IEUGWASdb v6.9.2 resource via the ieugwasr package version 0.1.5<sup>26</sup>. To 1106 1107 correct for multiple testing, we applied the false discovery rate (FDR) method, and we retained only those retinol/outcome pairs with estimates that were significant below the 1% FDR 1108 1109 threshold (q < 0.01). Subsequently, we investigated whether significant trait pairs colocalised 1110 using coloc v5.1.0 with default priors.

1111

Although the single IV approach is more conservative, power to detect causal effects can be 1112 boosted by using all available independent ( $r^2 < 0.001$ , 1000 genomes phase 3 European 1113 reference panel) genome-wide significant SNPs as IVs. The inverse-variance weighted 1114 estimator with multiplicative random effects (IVW-MRE) was utilised to estimate the effect of 1115 retinol on outcomes from IEUGWASdb for which at least 6 IVs were available in that 1116 GWAS<sup>112</sup>. The IVW approach has a zero percent breakdown level as it assumes all IVs are 1117 valid for use in Mendelian randomisation, which is often unrealistic in practice. We developed 1118 pipeline to prioritise the most reliable causal estimates from the IVW-MRE that survived 1119

1120 multiple-testing correction (q < 0.01). This involved identifying retinol MR estimates on traits for which the following applied: i) no significant heterogeneity (P < 0.05) between IV 1121 exposure-outcome effects tested with Cochran's  $Q^{113}$ , ii) a non-significant intercept of an MR-1122 Egger model that does not constrain the intercept to pass through the origin<sup>114</sup>, and iii) no 1123 1124 evidence that leaving out any single IV ablates the statistical significance (at least P < 0.05) of the estimate<sup>115</sup>. Traits satisfying these criteria were then assigned a tier (Tier #1, Tier #2, Tier 1125 1126 #3) based on the statistical significance of the retinol causal estimate using other MR methods besides the IVW-MRE that have different assumptions regarding IV validity. These were: the 1127 IVW with fixed effects (does not model heterogeneity like with MRE), the weighted median 1128 method<sup>116</sup>, the weighted mode method<sup>117</sup>, and the MR-Egger method<sup>114</sup>. The underlying 1129 assumptions and methodological considerations of using these methods have discussed 1130 extensively elsewhere<sup>118,119</sup>. Traits for which the effect of retinol was at least nominally 1131 statistically significant using all five methods were assigned as Tier #1, whilst four tests being 1132 statistically significant was Tier #2, and three tests being statistically significant was Tier #3. 1133 The *F*-statistic and  $I^2$  of the IVs was also assessed to ensure they were well powered (F > 10) 1134 and suited for MR-Egger ( $l^2 > 0.9$ ), respectively<sup>120</sup>. To investigate the effect of body fat 1135 1136 percentage on the retinol associated MRI indices, we used IVs from a non-overlapping GWAS of that trait  $(N=65,831)^{121}$ . We then repeated the above process of binary outcomes with at least 1137 1000 cases from FinnGen release 8, which is not included in the current version of 1138 1139 IEUGWASdb at time of analysis, to increase power to detect effects on disease endpoints.

1140

1141 We also systematically investigated continuous outcomes that may causally impact circulating retinol. Continuous outcomes were our focus as causal estimates from binary exposures are 1142 1143 difficult to interpret and are often less powered in the context of MR<sup>47</sup>. Exposures were filtered 1144 from phenotypes available in IEUGWASdb to retain continuous traits, with further filtering to identify traits with > 5 genome-wide significant, independent ( $r^2 < 0.001$ , 1000 genomes phase 1145 3 European reference panel) IVs available in the retinol GWAS. The same pipeline as above 1146 was then applied (IVW-MRE FDR < 0.01, followed by sensitivity analyses and tier 1147 assignment). The causal estimate of creatinine on retinol was a Tier #1 trait, and due to the 1148 pervasive polygenicity of creatinine afforded by its large sample size, we followed up this 1149 1150 relationship using the MR model "Causal Analysis Using Summary Effect Estimates" (CAUSE), as described elsewhere using the CAUSE R package v1.2.0<sup>52</sup>. Briefly, this method 1151 is a more polygenic approach and seeks to distinguish casual effects from correlated pleiotropy 1152 by fitting competing models that account for these terms and comparing them using ELPD. 1153

After using 1 million random variants to estimate nuisance parameters, LD clumping and thresholding was applied to the serum creatinine summary statistics (IEUGWASdb trait ID: met-d-creatinine) in line with the original CAUSE publication (P < 0.001,  $r^2 < 0.01$ , 1000 genomes phase 3 European reference panel). The competing CAUSE models were then fit (null, sharing, and causal), ensuring that all Pareto k estimates were < 0.5 during the model comparison using ELPD.

1160

We then performed a multivariable MR (MVMR) analysis to estimate causal effects of 1161 1162 creatinine on retinol conditioned on three major lipid species using GWAS from the global lipids genetics consortium (LDL, HDL, and triglycerides)<sup>122</sup>. MVMR was undertaken in 1163 accordance with previous work using the R packages MVMR v0.3 1164 and MendelianRandomization v0.6.0<sup>118</sup>. Briefly, this entailed identifying variants associated at 1165 genome-wide significance with at least one of the four exposures that are independent ( $r^2 <$ 1166 0.001), calculating a conditional *F*-statistic for multivariable instruments<sup>123</sup>, and applying four 1167 1168 MVMR models (IVW, Egger regression, Weighted Median, and a LASSO based penalised regression approach for selecting the optimal IV configuration) $^{124}$ . 1169

1170

# 1171 Drugs and perturbagens associated with circulating retinol

We also considered drugs that may influence circulating retinol. We searched genes prioritised 1172 1173 from our pipeline with an assigned direction of retinol-associated expression using DGIdb v4.2.0 and DrugBank v5 to identify retinol associated genes targeted by drugs<sup>125,126</sup>, outside of 1174 1175 known drugs that target RBP4 and TTR. Retained drug-gene interactions were restricted to those with known mechanism of action and > 2 lines of supporting evidence. We also utilised 1176 1177 computational signature mapping to identify pharmacological agents that may enhance or 1178 inhibit the expression of genes associated with circulating retinol. To boost power for signature 1179 mapping, we considered all gene that were nominally associated with retinol in the TWAS/PWAS (P < 0.05) that exhibited moderate colocalisation of a shared causal variant 1180  $(PP_{H4} > 0.4)$ . These genes were uploaded to the Connectivity Map Query online tool to quantify 1181 the similarity, termed connectivity, with drug perturbagen associated expression profiles, as 1182 outlined in detail elsewhere<sup>127</sup>. 1183

1184

#### 1185 **Polygenic scoring**

We used the independent TwinsUK replication cohort, described in a preceding section, toinvestigate retinol polygenic scores (PGS). PGS were applied to genotyped variants and high

confidence imputed variants ( $R^2 > 0.8$ ) in TwinsUK. There were two different methodologies 1188 implemented to construct PGS: LD clumping and thresholding (LD C+T) and a probabilistic 1189 1190 finemapping based method that scales variant effect sizes based on their posterior probability of causality, thereby upweighting signals more likely to be causal (RápidoPGS)<sup>128,129</sup>. In the 1191 1192 LD C+T approach, variants were clumped using the within sample LD of TwinsUK at the following *P*-value thresholds:  $5 \times 10^{-8}$ ,  $1 \times 10^{-5}$ ,  $1 \times 10^{-3}$ , 0.01, 0.05, 0.1, 0.5, and 1. Additive PGS 1193 1194 were then profiled using PRSice2 v2.3.5<sup>130</sup>. The RápidoPGS applies probabilistic finemapping (with Bayes' factors approximated using Wakefield's method) to independent LD blocks 1195 1196 genome-wide such that variant-wise posterior probabilities of causality can be estimated. This in essence is a 'shrinkage' approach to PGS to account for double-counting effects that arise 1197 due to correlated effect sizes induced by LD; however, does not inherently require an 1198 independent genotyped sample from the GWAS for tuning. Approximate Bayes' factors in 1199 each LD block were derived assuming a prior variance of 0.15, conventionally used for 1200 quantitative traits. This parameter choice was compared to a data driven approach to estimating 1201 the prior variance based on SNP heritability, as outlined elsewhere<sup>129</sup>. Variant-wise effect sizes 1202 1203 are multiplied by their posterior probabilities before PGS calculation, as above.

1204

1205 As we are using a twin cohort, there were two different approaches we utilised to tune the optimal PGS configuration from the LD C+T approach. Firstly, we randomly split the cohort 1206 1207 into a training (70% of participants) and test (30% of participants) partition. A linear mixed model was then fit in the training partition with fixed effects of PGS, age, and metabolomics 1208 1209 batch and a random effect of family ID to account for twin relatedness. This was applied for retinol measured at each of the three visits for all the *P*-value thresholds. The marginal  $R^2$  from 1210 1211 a null model with no PGS was subtracted from the full model to infer the best performing PGS in the training partition (mean marginal  $R^2$  across three visits). The variance explained of the 1212 best performing *P*-value threshold was then estimated using the same approach in the test 1213 partition. By way of comparison, we also split the twins into separate unrelated cohorts and 1214 1215 used one set as training and one as testing. Fixed effects instead of mixed effects linear 1216 regression was then implemented in a similar fashion to above, additionally covaried for five SNP derived principal components. We then repeated all the above for the two probabilistic 1217 1218 finemapping weighted PGS (prior variance = 0.15 and data driven prior variance).

- 1219
- 1220
- 1221

#### 1222 Normative modelling

We built a normative model of retinol as a function of age per study visit in TwinsUK. This 1223 was achieved using a generalised additive model for location ( $\mu$ ), scale ( $\sigma$ ), and shape 1224 (GAMLSS)<sup>131,132</sup>, implemented in R v4.4.1. The GAMLSS approach is useful in this 1225 application as it is semi-parametric and able to account for factors such as heteroskedasticity 1226 1227 and non-Gaussian distributions. Our modelling approach can be summarised as follows: we firstly fit a GAMLSS model in the full sample for a variety of GAMLSS distribution families 1228 implemented by the gamlss R package v5.4.12. The model on retinol at visit *i*, *i*  $\in$  {1,2,3} for 1229 each of the GAMLSS families set the  $\mu$  term as the first order fractional polynomial of age, 1230 along with metabolomics batch as an additional covariate, with the term  $\sigma$  just the first order 1231 fractional polynomial of age to model the scale of the distribution. The model fit of each of the 1232 1233 tested families was then assessed using the Bayesian information criterion (BIC) and the Akaike information criterion (AIC). We repeated the above also including measured body mass 1234 index (BMI) at that timepoint in the  $\mu$  term by way of comparison. We chose the GAMLSS 1235 family (Box-Cox t distribution) through considering the model performance (minimum AIC 1236 and BIC) over all three visits (Supplementary Text, Supplementary Figures 11-12). We then 1237 1238 split the cohort in half, separating the twins, and fit normative centile curves using the selected GAMLSS family to one half of each batch of retinol measurement, and computed deviations 1239 1240 on the other independent sample half on a per batch basis. We repeated this process with the modelling and deviation subsets reversed to compute deviations for all samples. Individuals 1241 whose measured retinol was above the model derived 95th percentile were classified as having 1242 supra-normal retinol for their age, while those below the 5th percentile were classified as 1243 1244 having infra-normal retinol. To guard against overfitting due to the relatedness of twins between the two subsets, we then performed all of the above just using one half of the twins as 1245 the full cohort for model fitting, followed by splitting this subset as described above. We tested 1246 the relationship between scaled retinol PGS (mean = 0, SD = 1) and infra-normal retinol at 1247 each visit was tested in half of the cohort (unrelated) using binomial logistic regression 1248 additionally covaried for five SNP derived PCs. The same models were also constructed for 1249 supra-normal individuals. 1250

1251

#### 1252 Software and operating systems

The primary analyses in this manuscript were performed either on a MacBook Pro (OS X:Ventura 13.3), an in-house linux cluster (Ubuntu 18.04.5 LTS), or the High-Performance

Computing Research Compute Grid of the University of Newcastle [Red Hat Enterprise Linux
release 8.1 (Ootpa)]. The primary R version utilised was version 4.1.1 (2021-08-10), with some
additional analyses using R version 4.0.3 (2020-10-10) (linux cluster). The Python version
utilised was either Python 2.7.17 or Python 3.6.9, depending on the requirements of the
analyses.

1260

# 1261 DATA AVAILABILITY

1262 Genome-wide summary statistics will be uploaded to GWAS catalog upon final publication. 1263 In the interim, summary statistics can also be found at the following: 10.5281/zenodo.7905523. 1264 TwinsUK data can be accessed bv approve researchers upon application 1265 (https://twinsuk.ac.uk/resources-for-researchers/our-data/).

1266

# 1267 CODE AVAILABILITY

1268 Code used in this study is freely available at the following GitHub repository -

1269 <u>https://github.com/Williamreay/Retinol\_GWAS\_code.</u>

1270

#### 1271 ACKNOWLEDGEMENTS

TwinsUK is funded by the Wellcome Trust, Medical Research Council, Versus Arthritis, 1272 1273 European Union Horizon 2020, Chronic Disease Research Foundation (CDRF), Zoe Ltd, the National Institute for Health and Care Research (NIHR) Clinical Research Network (CRN) and 1274 Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in 1275 partnership with King's College London. P.S. was supported by a Rutherford Fund Fellowship 1276 1277 from the Medical Research Council (grant no. MR/S003746/1). Participants in the INTERVAL 1278 trial were recruited with the active collaboration of NHS Blood and Transplant England (www.nhsbt.nhs.uk), which has supported field work and other elements of the trial. DNA 1279 1280 extraction and genotyping were co-funded by the National Institute for Health and Care Research (NIHR), the NIHR BioResource (http://bioresource.nihr.ac.uk) and the NIHR 1281 1282 Cambridge Biomedical Research Centre (BRC-1215-20014). The academic coordinating centre for INTERVAL was supported by core funding from the: NIHR Blood and Transplant 1283 Research Unit (BTRU) in Donor Health and Genomics (NIHR BTRU-2014-10024), NIHR 1284 BTRU in Donor Health and Behaviour (NIHR203337), UK Medical Research Council 1285 1286 (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and NIHR Cambridge BRC (BRC-1215-20014; NIHR203312) [\*]. 1287

1288 Metabolon metabolomics assays in INTERVAL were funded by the: NIHR BioResource, NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [\*], Wellcome Trust grant 1289 1290 number 206194 and BioMarin Pharmaceutical, Inc. The academic coordinating centre thank blood donor centre staff and blood donors for participating in the INTERVAL trial. This work 1291 1292 was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research 1293 1294 Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research 1295 1296 and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. For the purpose of open access, the author(s) has 1297 applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript 1298 version arising from this submission.\*The views expressed are those of the author(s) and not 1299 necessarily those of the NIHR, NHSBT or the Department of Health and Social Care. Access 1300 to the TwinsUK cohort for this study was funded by a Hunter Medical Research Institute 1301 1302 (Newcastle, Australia) Precision Medicine Research Program Pilot Grant (W.R.R). C.E.C. is 1303 supported by an investigator grant from the National Health and Medical Research Council (NHMRC). M.A.D is supported by an investigator grant from the National Health and Medical 1304 1305 Research Council (NHMRC). P.S. was supported by a Rutherford Fund Fellowship from the Medical Research Council (grant no. MR/S003746/1). We also acknowledge and thank all 1306 1307 participants in the genetic studies included in this paper.

1308

#### **1309 ETHICS DECLARATION**

1310 P.S. is now a full-time employee of GlaxoSmithKline. The remaining authors declare no

- 1311 competing financial interests.
- 1312

# 1313 AUTHOR CONTRIBUTIONS

W.R.R designed the study and was the primary analyst. D.J.K. assisted with developing the
phenome-wide Mendelian randomisation pipeline. M.A.D developed the normative modelling
pipeline. Z.F.G. performed the signature mapping analyses. P.S performed quality control on
the INTERVAL data prior to GWAS. K.K performed the INTERVAL GWAS. E.D.C and
C.E.C provided input into the TwinsUK retinol quality control, and the interpretation of the
clinical associations. L.A.G assisted with data curation and preparation of the manuscript.
A.M.M and D.A provided the ATBC/PLCO data. M.J.C contributed to drafting manuscript and

provided funding. All authors contributed to interpretation of the results and the finalmanuscript.

1323

#### 1324 **REFERENCES**

- 1325 1. Blomhoff, R. & Blomhoff, H. K. Overview of retinoid metabolism and function. J
- 1326 *Neurobiol* **66**, 606–630 (2006).
- 1327 2. Reay, W. R. & Cairns, M. J. The role of the retinoids in schizophrenia: genomic and
- 1328 clinical perspectives. *Mol Psychiatry* **25**, 706–718 (2020).
- 1329 3. D'Ambrosio, D. N., Clugston, R. D. & Blaner, W. S. Vitamin A metabolism: an update.
- 1330 *Nutrients* **3**, 63–103 (2011).
- 1331 4. Britton, G. Carotenoid research: History and new perspectives for chemistry in biological
- 1332 systems. Biochimica et Biophysica Acta (BBA) Molecular and Cell Biology of Lipids
- **1333 1865**, 158699 (2020).
- 1334 5. Duester, G., Mic, F. A. & Molotkov, A. Cytosolic retinoid dehydrogenases govern
- 1335 ubiquitous metabolism of retinol to retinaldehyde followed by tissue-specific metabolism
- to retinoic acid. *Chem Biol Interact* **143–144**, 201–210 (2003).
- 1337 6. Cunningham, T. J. & Duester, G. Mechanisms of retinoic acid signalling and its roles in
- 1338 organ and limb development. *Nat Rev Mol Cell Biol* **16**, 110–123 (2015).
- 1339 7. Li, Y., Wongsiriroj, N. & Blaner, W. S. The multifaceted nature of retinoid transport and
  1340 metabolism. *Hepatobiliary Surg Nutr* 3, 126–139 (2014).
- 1341 8. Kanai, M., Raz, A. & Goodman, D. S. Retinol-binding protein: the transport protein for
- 1342 vitamin A in human plasma. *J Clin Invest* 47, 2025–2044 (1968).
- 1343 9. van Bennekum AM, null et al. Biochemical basis for depressed serum retinol levels in
- transthyretin-deficient mice. J Biol Chem 276, 1107–1113 (2001).
- 1345 10. Gudas, L. J. Synthetic Retinoids Beyond Cancer Therapy. Annu Rev Pharmacol
- **1346** *Toxicol* **62**, 155–175 (2022).

- 1347 11. Chisholm, D. R. & Whiting, A. Design of synthetic retinoids. *Methods Enzymol* 637,
  1348 453–491 (2020).
- 1349 12. Behl, T. et al. Therapeutic insights elaborating the potential of retinoids in
- 1350 Alzheimer's disease. Front. Pharmacol. 13, 976799 (2022).
- 1351 13. Kim, J. A., Jang, J.-H. & Lee, S.-Y. An Updated Comprehensive Review on Vitamin
- 1352 A and Carotenoids in Breast Cancer: Mechanisms, Genetics, Assessment, Current
- 1353 Evidence, and Future Clinical Implications. *Nutrients* **13**, 3162 (2021).
- 1354 14. Harirchian, M. H., Mohammadpour, Z., Fatehi, F., Firoozeh, N. & Bitarafan, S. A
- 1355 systematic review and meta-analysis of randomized controlled trials to evaluating the trend
- 1356 of cytokines to vitamin A supplementation in autoimmune diseases. *Clinical Nutrition* **38**,
- **1357** 2038–2044 (2019).
- 1358 15. Leelakanok, N., D'Cunha, R. R., Sutamtewagul, G. & Schweizer, M. L. A systematic
- review and meta-analysis of the association between vitamin A intake, serum vitamin A,

and risk of liver cancer. *Nutr Health* **24**, 121–131 (2018).

- 1361 16. O'Connor, E. A. et al. Vitamin and Mineral Supplements for the Primary Prevention
- 1362 of Cardiovascular Disease and Cancer: Updated Evidence Report and Systematic Review

1363 for the US Preventive Services Task Force. *JAMA* **327**, 2334 (2022).

- 1364 17. Huang, J., Weinstein, S. J., Yu, K., Männistö, S. & Albanes, D. Association between
- serum retinol and overall and cause-specific mortality in a 30-year prospective cohort
- 1366 study. *Nat Commun* **12**, 6418 (2021).
- 136718.Bennett, D. A. & Du, H. An Overview of Methods and Exemplars of the Use of
- 1368Mendelian Randomisation in Nutritional Research. Nutrients 14, 3408 (2022).
- 1369 19. Reay, W. R. & Cairns, M. J. Advancing the use of genome-wide association studies
- 1370 for drug repurposing. *Nat Rev Genet* **22**, 658–671 (2021).

- 1371 20. Gueguen, S. *et al.* Genetic and environmental contributions to serum retinol and
- 1372 alpha-tocopherol concentrations: the Stanislas Family Study. *Am J Clin Nutr* 81, 1034–
  1373 1044 (2005).
- 1374 21. Ferrucci, L. et al. Common variation in the beta-carotene 15,15'-monooxygenase 1
- 1375 gene affects circulating levels of carotenoids: a genome-wide association study. *Am J Hum*
- 1376 *Genet* 84, 123–133 (2009).
- 1377 22. Mondul, A. M. *et al.* Genome-wide association study of circulating retinol levels.
- 1378 *Human Molecular Genetics* **20**, 4724–4731 (2011).
- 1379 23. Revez, J. A. et al. Genome-wide association study identifies 143 loci associated with
- 1380 25 hydroxyvitamin D concentration. *Nat Commun* 11, 1647 (2020).
- 1381 24. Manousaki, D. et al. Genome-wide Association Study for Vitamin D Levels Reveals
- 1382 69 Independent Loci. *The American Journal of Human Genetics* **106**, 327–337 (2020).
- 1383 25. Manousaki, D. et al. Low-Frequency Synonymous Coding Variation in CYP2R1 Has
- 1384 Large Effects on Vitamin D Levels and Risk of Multiple Sclerosis. *Am J Hum Genet* 101,
- 1385 227–238 (2017).
- 1386 26. Elsworth, B. et al. The MRC IEU OpenGWAS data infrastructure.
- 1387 http://biorxiv.org/lookup/doi/10.1101/2020.08.10.244293 (2020)
- doi:10.1101/2020.08.10.244293.
- 1389 27. Perez-Martinez, P. et al. Association between glucokinase regulatory protein (GCKR)
- and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations
- in fasting, postprandial, and fenofibrate-treated states. *The American Journal of Clinical*
- 1392 *Nutrition* **89**, 391–399 (2009).
- 1393 28. Fernandes Silva, L., Vangipurapu, J., Kuulasmaa, T. & Laakso, M. An intronic
- 1394 variant in the GCKR gene is associated with multiple lipids. *Sci Rep* 9, 10240 (2019).

- 1395 29. Yeh, K.-H. *et al.* Pleiotropic Effects of Common and Rare GCKR Exonic Mutations
  1396 on Cardiometabolic Traits. *Genes* 13, 491 (2022).
- 1397 30. Zelent, B. *et al.* Analysis of the co-operative interaction between the allosterically
- 1398 regulated proteins GK and GKRP using tryptophan fluorescence. *Biochemical Journal*
- **459**, 551–564 (2014).
- 1400 31. Lai, C. S. L. FOXP2 expression during brain development coincides with adult sites
- 1401 of pathology in a severe speech and language disorder. *Brain* **126**, 2455–2462 (2003).
- 1402 32. Mehta, M. B. *et al.* Hepatic protein phosphatase 1 regulatory subunit 3B (Ppp1r3b)
- 1403 promotes hepatic glycogen synthesis and thereby regulates fasting energy homeostasis. J
- 1404 *Biol Chem* 292, 10444–10454 (2017).
- 1405 33. Russell, R. *et al.* Loss of the transcription factor MAFB limits β-cell derivation from
  1406 human PSCs. *Nat Commun* 11, 2742 (2020).
- 1407 34. Artner, I. et al. MafA and MafB regulate genes critical to beta-cells in a unique
- temporal manner. *Diabetes* **59**, 2530–2539 (2010).
- 1409 35. Leask, M. et al. Functional Urate-Associated Genetic Variants Influence Expression
- 1410 of lincRNAs LINC01229 and MAFTRR. *Front Genet* 9, 733 (2018).
- 1411 36. Werth, M. et al. Transcription factor TFCP2L1 patterns cells in the mouse kidney
- 1412 collecting ducts. *eLife* **6**, e24265 (2017).
- 1413 37. Ortega-Azorín, C. et al. Amino Acid Change in the Carbohydrate Response Element
- 1414 Binding Protein Is Associated With Lower Triglycerides and Myocardial Infarction
- 1415 Incidence Depending on Level of Adherence to the Mediterranean Diet in the PREDIMED
- 1416 Trial. Circ Cardiovasc Genet 7, 49–58 (2014).
- 1417 38. Dentin, R. et al. Liver-Specific Inhibition of ChREBP Improves Hepatic Steatosis and
- 1418 Insulin Resistance in *ob/ob* Mice. *Diabetes* **55**, 2159–2170 (2006).

- 1419 39. Kathiresan, S. et al. Six new loci associated with blood low-density lipoprotein
- cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. *Nat Genet* 40,
  189–197 (2008).
- 1422 40. Beurel, E., Grieco, S. F. & Jope, R. S. Glycogen synthase kinase-3 (GSK3):
- regulation, actions, and diseases. *Pharmacol Ther* **148**, 114–131 (2015).
- 1424 41. Mariotti, L., Pollock, K. & Guettler, S. Regulation of Wnt/β-catenin signalling by
- tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding. *Br J Pharmacol* 174, 4611–
  4636 (2017).
- 1427 42. Namwanje, M. & Brown, C. W. Activins and Inhibins: Roles in Development,
- 1428 Physiology, and Disease. *Cold Spring Harb Perspect Biol* **8**, a021881 (2016).
- 1429 43. Nono Nankam, P. A. & Blüher, M. Retinol-binding protein 4 in obesity and metabolic

1430dysfunctions. Molecular and Cellular Endocrinology 531, 111312 (2021).

- 1431 44. Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation
- studies: a guide, glossary, and checklist for clinicians. *BMJ* k601 (2018)
- 1433 doi:10.1136/bmj.k601.
- 1434 45. Sanderson, E. et al. Mendelian randomization. Nat Rev Methods Primers 2, 6 (2022).
- 1435 46. McWhinney, S. R. et al. Obesity and brain structure in schizophrenia ENIGMA
- 1436 study in 3021 individuals. *Mol Psychiatry* **27**, 3731–3737 (2022).
- 1437 47. Burgess, S. & Labrecque, J. A. Mendelian randomization with a binary exposure
- 1438 variable: interpretation and presentation of causal estimates. *Eur. J. Epidemiol.* **33**, 947–
- **1439** 952 (2018).
- 1440 48. Hada, M., Mondul, A. M., Weinstein, S. J. & Albanes, D. Serum Retinol and Risk of
- 1441 Overall and Site-Specific Cancer in the ATBC Study. *American Journal of Epidemiology*
- **1442 189**, 532–542 (2020).

- 1443 49. Dragnev, K. H. *et al.* A phase I/II study of bexarotene with carboplatin and weekly
- 1444 paclitaxel for the treatment of patients with advanced non-small cell lung cancer. *J Thorac*

1445 *Dis* 10, 5531–5537 (2018).

- 1446 50. Olsen, T. et al. Creatinine, total cysteine and uric acid are associated with serum
- retinol in patients with cardiovascular disease. *Eur J Nutr* **59**, 2383–2393 (2020).
- 1448 51. Kučerová, K. et al. Determination of urinary retinol and creatinine as an early

sensitive marker of renal dysfunction. *J Chromatogr A* **1607**, 460390 (2019).

- 1450 52. Morrison, J., Knoblauch, N., Marcus, J. H., Stephens, M. & He, X. Mendelian
- 1451 randomization accounting for correlated and uncorrelated pleiotropic effects using
- 1452 genome-wide summary statistics. *Nat Genet* **52**, 740–747 (2020).
- 1453 53. Shinde, V. et al. Definition of transcriptome-based indices for quantitative
- 1454 characterization of chemically disturbed stem cell development: introduction of the STOP-

1455 Toxukn and STOP-Toxukk tests. *Arch Toxicol* **91**, 839–864 (2017).

- 1456 54. Krug, A. K. *et al.* Human embryonic stem cell-derived test systems for developmental
  1457 neurotoxicity: a transcriptomics approach. *Arch Toxicol* 87, 123–143 (2013).
- 1458 55. Meganathan, K. et al. Neuronal developmental gene and miRNA signatures induced
- by histone deacetylase inhibitors in human embryonic stem cells. *Cell Death Dis* 6, e1756(2015).
- 1461 56. Stephensen, C. B. & Gildengorin, G. Serum retinol, the acute phase response, and the
- apparent misclassification of vitamin A status in the third National Health and Nutrition
- 1463 Examination Survey, *The American Journal of Clinical Nutrition* **72**, 1170–1178 (2000).
- 1464 57. Inoue, E. et al. Identification of Glucose Transporter 4 Knockdown-dependent
- 1465 Transcriptional Activation Element on the Retinol Binding Protein 4 Gene Promoter and
- 1466 Requirement of the 20 S Proteasome Subunit for Transcriptional Activity. *Journal of*
- 1467 *Biological Chemistry* **285**, 25545–25553 (2010).

- 1468 58. Kiser, P. D., Golczak, M. & Palczewski, K. Chemistry of the retinoid (visual) cycle.
- 1469 *Chem Rev* 114, 194–232 (2014).
- 1470 59. Hall, J. A., Grainger, J. R., Spencer, S. P. & Belkaid, Y. The Role of Retinoic Acid in
- 1471 Tolerance and Immunity. *Immunity* **35**, 13–22 (2011).
- 1472 60. Stefanovic, S. & Zaffran, S. Mechanisms of retinoic acid signaling during
- 1473 cardiogenesis. *Mechanisms of Development* 143, 9–19 (2017).
- 1474 61. van Erp, T. G. M. et al. Cortical Brain Abnormalities in 4474 Individuals With
- 1475 Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics
- 1476 Through Meta Analysis (ENIGMA) Consortium. *Biol Psychiatry* 84, 644–654 (2018).
- 1477 62. Reay, W. R. et al. Polygenic disruption of retinoid signalling in schizophrenia and a
- severe cognitive deficit subtype. *Mol Psychiatry* **25**, 719–731 (2020).
- 1479 63. Crandall, J. et al. 13-cis-retinoic acid suppresses hippocampal cell division and
- 1480 hippocampal-dependent learning in mice. *Proc Natl Acad Sci U S A* **101**, 5111–5116
- 1481 (2004).
- 1482 64. Bremner, J. D., Shearer, K. D. & McCaffery, P. J. Retinoic acid and affective
- 1483 disorders: the evidence for an association. *J Clin Psychiatry* **73**, 37–50 (2012).
- 1484 65. Li, C. et al. Use of isotretinoin and risk of depression in patients with acne: a
- systematic review and meta-analysis. *BMJ Open* **9**, e021549 (2019).
- 1486 66. Lerner, V. et al. The retinoid X receptor agonist bexarotene relieves positive
- 1487 symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled
- 1488 multicenter trial. *J Clin Psychiatry* **74**, 1224–1232 (2013).
- 1489 67. Tanprasertsuk, J. et al. Serum Carotenoids, Tocopherols, Total n-3 Polyunsaturated
- 1490 Fatty Acids, and n-6/n-3 Polyunsaturated Fatty Acid Ratio Reflect Brain Concentrations in
- a Cohort of Centenarians. *The Journals of Gerontology: Series A* 74, 306–314 (2019).

- 1492 68. Staley, J. R. & Burgess, S. Semiparametric methods for estimation of a nonlinear
- 1493 exposure-outcome relationship using instrumental variables with application to Mendelian
- 1494 randomization. *Genet. Epidemiol.* **41**, 341–352 (2017).
- 1495 69. Burgess, S. *et al.* Guidelines for performing Mendelian randomization investigations.
- 1496 *Wellcome Open Res* **4**, 186 (2019).
- 1497 70. Moore, C. *et al.* The INTERVAL trial to determine whether intervals between blood
- donations can be safely and acceptably decreased to optimise blood supply: study protocol
- 1499 for a randomised controlled trial. *Trials* **15**, 363 (2014).
- 1500 71. Bomba, L. et al. Whole-exome sequencing identifies rare genetic variants associated
- 1501 with human plasma metabolites. *The American Journal of Human Genetics* **109**, 1038–
- 1502 1054 (2022).
- 1503 72. Hail Team. Hail 0.2.
- 1504 73. Yin, X. *et al.* Genome-wide association studies of metabolites in Finnish men identify
  1505 disease-relevant loci. *Nat Commun* 13, 1644 (2022).
- 1506 74. Laakso, M. et al. The Metabolic Syndrome in Men study: a resource for studies of
- 1507 metabolic and cardiovascular diseases. *J Lipid Res* **58**, 481–493 (2017).
- 1508 75. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods,
- 1509 participant characteristics, and compliance. The ATBC Cancer Prevention Study Group.
- **1510** *Ann Epidemiol* **4**, 1–10 (1994).
- 1511 76. Hayes, R. B. et al. Methods for etiologic and early marker investigations in the PLCO
- trial. *Mutat Res* **592**, 147–154 (2005).
- 1513 77. Pasaniuc, B. et al. Fast and accurate imputation of summary statistics enhances
- evidence of functional enrichment. *Bioinformatics* **30**, 2906–2914 (2014).
- 1515 78. Long, T. et al. Whole-genome sequencing identifies common-to-rare variants
- associated with human blood metabolites. *Nat Genet* **49**, 568–578 (2017).

- 1517 79. Moayyeri, A., Hammond, C. J., Hart, D. J. & Spector, T. D. The UK Adult Twin
- 1518 Registry (TwinsUK Resource). *Twin Res Hum Genet* 16, 144–149 (2013).
- 1519 80. Shin, S.-Y. et al. An atlas of genetic influences on human blood metabolites. Nat
- 1520 *Genet* **46**, 543–550 (2014).
- 1521 81. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and
- 1522 richer datasets. *GigaSci* **4**, 7 (2015).
- 1523 82. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association
  1524 studies. *Bioinformatics* 26, 2867–2873 (2010).
- 1525 83. Price, A. L. et al. Long-range LD can confound genome scans in admixed
- 1526 populations. Am. J. Hum. Genet. 83, 132–135; author reply 135-139 (2008).
- 1527 84. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping
- and annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
- 1529 85. Zhou, H. et al. FAVOR: functional annotation of variants online resource and
- annotator for variation across the human genome. *Nucleic Acids Res* **51**, D1300–D1311

1531 (2023).

- 1532 86. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
  1533 population. *Nature* 613, 508–518 (2023).
- 1534 87. Liu, Y. & Xie, J. Cauchy Combination Test: A Powerful Test With Analytic *p* -Value
- 1535 Calculation Under Arbitrary Dependency Structures. *Journal of the American Statistical*1536 *Association* 115, 393–402 (2020).
- 1537 88. Liu, Y. *et al.* ACAT: A Fast and Powerful p Value Combination Method for Rare-
- 1538 Variant Analysis in Sequencing Studies. Am. J. Hum. Genet. 104, 410–421 (2019).
- 1539 89. Schizophrenia Working Group of the Psychiatric Genomics Consortium et al. LD
- 1540 Score regression distinguishes confounding from polygenicity in genome-wide association
- 1541 studies. *Nat Genet* 47, 291–295 (2015).

- 1542 90. Speed, D. & Balding, D. J. SumHer better estimates the SNP heritability of complex
- traits from summary statistics. *Nat Genet* **51**, 277–284 (2019).
- 1544 91. Speed, D., Holmes, J. & Balding, D. J. Evaluating and improving heritability models
- using summary statistics. *Nat Genet* **52**, 458–462 (2020).
- 1546 92. Finucane, H. K. et al. Partitioning heritability by functional annotation using genome-
- 1547 wide association summary statistics. *Nat Genet* **47**, 1228–1235 (2015).
- 1548 93. Stephens, M. False discovery rates: a new deal. *Biostatistics* 18, 275–294 (2017).
- 1549 94. Boyle, E. A., Li, Y. I. & Pritchard, J. K. An Expanded View of Complex Traits: From
- 1550 Polygenic to Omnigenic. *Cell* **169**, 1177–1186 (2017).
- 1551 95. Reay, W. R. et al. The genetic architecture of pneumonia susceptibility implicates
- 1552 mucin biology and a relationship with psychiatric illness. *Nat Commun* **13**, 3756 (2022).
- 1553 96. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across
  1554 human tissues. *Science* 369, 1318–1330 (2020).
- 1555 97. Wen, X., Pique-Regi, R. & Luca, F. Integrating molecular QTL data into genome-
- 1556 wide genetic association analysis: Probabilistic assessment of enrichment and
- 1557 colocalization. *PLoS Genet* **13**, e1006646 (2017).
- 1558 98. Zhang, J. et al. Plasma proteome analyses in individuals of European and African
- ancestry identify cis-pQTLs and models for proteome-wide association studies. *Nat Genet*54, 593–602 (2022).
- 1561 99. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD:
- predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Research* 47, D886–D894 (2019).
- 1564 100. Boyle, A. P. et al. Annotation of functional variation in personal genomes using
- 1565 RegulomeDB. *Genome Res* 22, 1790–1797 (2012).

- 1566 101. Ghoussaini, M. et al. Open Targets Genetics: systematic identification of trait-
- 1567 associated genes using large-scale genetics and functional genomics. *Nucleic Acids*

1568 *Research* **49**, D1311–D1320 (2021).

- 1569 102. Wakefield, J. Bayes factors for genome-wide association studies: comparison with P-
- 1570 values. *Genet Epidemiol* **33**, 79–86 (2009).
- 1571 103. Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic
- association studies using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).
- 1573 104. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package
- 1574 for differential expression analysis of digital gene expression data. *Bioinformatics* 26,

1575 139–140 (2010).

- 1576 105. Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and
- 1577 conversions of gene lists (2019 update). *Nucleic Acids Research* **47**, W191–W198 (2019).
- 1578 106. Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association
- 1579 studies. Nat. Genet. 48, 245–252 (2016).
- 1580 107. Reay, W. R. & Cairns, M. J. Pairwise common variant meta-analyses of
- schizophrenia with other psychiatric disorders reveals shared and distinct gene and gene-
- 1582 set associations. *Transl Psychiatry* **10**, 134 (2020).
- 108. Adams, D. M., Reay, W. R. & Cairns, M. J. Multiomic prioritisation of risk genes for
  anorexia nervosa. *Psychol Med* 1–9 (2023) doi:10.1017/S0033291723000235.
- 1585 109. Reay, W. R. et al. Genetics-informed precision treatment formulation in
- schizophrenia and bipolar disorder. *The American Journal of Human Genetics* 109, 1620–
  1637 (2022).
- 1588 110. Reay, W. R. et al. Genetic association and causal inference converge on
- 1589 hyperglycaemia as a modifiable factor to improve lung function. *eLife* **10**, e63115 (2021).

- 1590 111. Wainberg, M. *et al.* Opportunities and challenges for transcriptome-wide association
  1591 studies. *Nat Genet* 51, 592–599 (2019).
- 1592 112. Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis
- 1593 with multiple genetic variants using summarized data. *Genet. Epidemiol.* **37**, 658–665
- 1594 (2013).
- 1595 113. Bowden, J., Hemani, G. & Davey Smith, G. Invited Commentary: Detecting
- 1596 Individual and Global Horizontal Pleiotropy in Mendelian Randomization-A Job for the
- 1597 Humble Heterogeneity Statistic? *Am J Epidemiol* **187**, 2681–2685 (2018).
- 1598 114. Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
- 1599 instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol

**1600 44**, 512–525 (2015).

- 1601 115. Burgess, S., Bowden, J., Fall, T., Ingelsson, E. & Thompson, S. G. Sensitivity
- 1602 Analyses for Robust Causal Inference from Mendelian Randomization Analyses with

1603 Multiple Genetic Variants. *Epidemiology* **28**, 30–42 (2017).

- 1604 116. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in
- 1605 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median

1606 Estimator. *Genet. Epidemiol.* **40**, 304–314 (2016).

- 1607 117. Burgess, S., Zuber, V., Gkatzionis, A. & Foley, C. N. Modal-based estimation via
- 1608 heterogeneity-penalized weighting: model averaging for consistent and efficient estimation
- in Mendelian randomization when a plurality of candidate instruments are valid. Int J
- 1610 *Epidemiol* 47, 1242–1254 (2018).
- 1611 118. Reay, W. R. *et al.* Genetic estimates of correlation and causality between blood-based
  1612 biomarkers and psychiatric disorders. *Sci. Adv.* 8, eabj8969 (2022).
- 1613 119. Slob, E. A. W. & Burgess, S. A comparison of robust Mendelian randomization
- 1614 methods using summary data. *Genetic Epidemiology* 44, 313–329 (2020).

- 1615 120. Bowden, J. *et al.* Assessing the suitability of summary data for two-sample Mendelian
- 1616 randomization analyses using MR-Egger regression: the role of the I2 statistic. *Int J*
- 1617 *Epidemiol* **45**, 1961–1974 (2016).
- 1618 121. Lu, Y. et al. New loci for body fat percentage reveal link between adiposity and
- 1619 cardiometabolic disease risk. *Nat Commun* 7, 10495 (2016).
- 1620 122. Willer, C. J. et al. Discovery and refinement of loci associated with lipid levels. Nat
- 1621 *Genet* 45, 1274–1283 (2013).
- 1622 123. Sanderson, E., Spiller, W. & Bowden, J. Testing and Correcting for Weak and
- 1623 *Pleiotropic Instruments in Two-Sample Multivariable Mendelian Randomisation.*
- 1624 http://biorxiv.org/lookup/doi/10.1101/2020.04.02.021980 (2020)
- doi:10.1101/2020.04.02.021980.
- 1626 124. Grant, A. J. & Burgess, S. Pleiotropy robust methods for multivariable Mendelian
  1627 randomization. *Statistics in Medicine* 40, 5813–5830 (2021).
- 1628 125. Freshour, S. et al. Integration of the Drug-Gene Interaction Database (DGIdb) with
- 1629 *open crowdsource efforts*. http://biorxiv.org/lookup/doi/10.1101/2020.09.18.301721
- 1630 (2020) doi:10.1101/2020.09.18.301721.
- 1631 126. Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for
- 1632 2018. Nucleic Acids Res 46, D1074–D1082 (2018).
- 1633 127. Subramanian, A. et al. A Next Generation Connectivity Map: L1000 Platform and the
- 1634 First 1,000,000 Profiles. *Cell* **171**, 1437-1452.e17 (2017).
- 1635 128. International Schizophrenia Consortium et al. Common polygenic variation
- 1636 contributes to risk of schizophrenia and bipolar disorder. *Nature* **460**, 748–752 (2009).
- 1637 129. Reales, G., Vigorito, E., Kelemen, M. & Wallace, C. RápidoPGS: a rapid polygenic
- score calculator for summary GWAS data without a test dataset. *Bioinformatics* **37**, 4444–
- **1639 4450** (2021).

- 1640 130. Choi, S. W. & O'Reilly, P. F. PRSice-2: Polygenic Risk Score software for biobank-
- 1641 scale data. *GigaScience* **8**, giz082 (2019).
- 1642 131. Stasinopoulos, M. D., Rigby, R. A., Heller, G. Z., Voudouris, V. & Bastiani, F. D.
- 1643 Flexible Regression and Smoothing: Using GAMLSS in R. (Chapman and Hall/CRC,
- 1644 2017). doi:10.1201/b21973.
- 1645 132. Rigby, R. A. & Stasinopoulos, D. M. Generalized Additive Models for Location,
- 1646 Scale and Shape. *Journal of the Royal Statistical Society Series C: Applied Statistics* 54,
- 1647 507–554 (2005).

1648